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1. INTRODUCTION 
Breast cancer represents a heterogeneous group of tumours with varied morphologic and 
biological features, behavior, and response to therapy (Rakha and Ellis, 2011). The above 
mentioned heterogeneity is well recognized and raises the need for a revision of the World 
Health Organization (WHO) classification, which was based on morphological features alone 
(Eusebi, 2010). The beginning of a new era in cancer research is marked by the development 
of methods to measure the expression of thousands of genes in tumour and in normal tissues. 
The regulation of gene expression occurs through different molecular mechanisms such as the 
transcriptional,  transduction and  post-transcriptional control. The first mechanism operates 
at the frequency of transcription of messenger RNA from its own template DNA. The 
transduction control regulates the speed with which a molecule of mRNA is translated into a 
protein. The post-transcriptional control occurs in the moment when modulation of protein 
synthesis is required, adjusting the speed or degrading a transcript that is already synthesized. 
The functionality of these systems enables the processing of complex gene expression profiles 
(Watson, 2008). Variation in transcriptional programs accounts for much of the biological 
diversity of human cells and tumours. In each cell, signal transduction and regulatory systems 
transduce information from the cell identity to its environmental status, thereby controlling 
the level of expression of every gene in the genome (Perou et al, 2000; Sorlie et al. 2001). 
The analysis of gene expression is the realization of the reform of tumour taxonomy, in 
predicting the metastatic potential, prognosis and response to therapy. It is also used to reveal 
patterns of gene expression that are dependent on the mutation of a single oncogene, and 
finally, in analyzing the effects of hormones and environmental influences on carcinogenesis 
(Robbins and Cotran, 2010). 
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Sorlie et al. (2001) laid the foundations for the new taxonomy demonstrating that changes in 
patterns of gene expression, analyzed by cDNA microarray techniques and hierarchical 
clustering, allowed a ‘molecular portrait’ to be defined for each tumour.  
Recently, molecular characterization in human breast cancer has also been applied to the 
metastasing lymph nodes and to the systemic metastases (Wu et al., 2008). 
As in Human Medicine, mammary gland tumours commonly occur also in female dogs 
(Gama et al., 2008) and cats (Morris et al., 2008), representing a remarkably heterogeneous 
group in terms of morphology and biological behaviour (Nielsen et al., 2004). In the last 
decades, veterinary attention has focused on the identification of reliable prognostic factors, 
such as tumour size, histologic type, histologic grade, lymph node status (Misdorp et al., 
1999; Gama et al.2008; Sassi et al. 2010) and protein expression profile (Gama et al., 2008; 
Sassi et al., 2010), essential in order to estimate the individual risk of unfavourable clinical 
outcome (Misdorp, 2002; Zaidan, 2008). Gama et al. in 2008 and Sassi et al. in 2010  were 
the first who applied, from human medicine, an immunohistochemical algorithm and 
identified molecular phenotypes in canine mammary tumours. 
Therefore, aims, developed as projects, of the past three years have been (1) to define the 
molecular phenotype of feline mammary carcinomas and their lymph node metastases 
according to a previous modified algorithm and to demonstrate the different relation between 
the primary tumour and lymph node metastasis, (2) to analyze, in female dogs, the 
relationship between the primary mammary tumor and its lymph node metastasis based on 
immunohistochemical molecular characterization in order to develop the most specific 
prognostic-predictive models and targeted therapeutic options, and (3) to evaluate the 
molecular trend of cancer from its primary location to systemic metastases  cats and  dogs 
with mammary tumors. Before  the following research, no literature reports have addressed 
the immunophenotyping of feline mammary carcinomas. 
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 In order to make this study more complete, a parallel project  has been carried out on the 
myoepithelial cells of canine mammary tumours. In canine normal mamamary gland, the 
lumina are delimitated by an inner layer of polarized epithelial cells resting on two outer or 
basal layers of epithelial and myoepithelial cells (Ramalho et al., 2006). Both basal and 
myoepithelial cells synthesize the basement membrane of ducts and alveoli and form a 
structural barrier between the luminal epithelial cells and the surrounding stroma (Polyak and 
Hu, 2006). The studies on mammary tumours, particularly in dogs, have drawn gradually 
increasing attention not exclusively to the epithelial component, but also to the myoepithelial 
cells. Myoepithelial cell proliferation is a frequent finding in the so-called complex and mixed 
patterns (Misdorp et al., 1999) but it is an uncommon feature of breast cancer in women 
(Sassi et al., 2010) and in cats. The lack of complete information on a valid panel of markers 
for the identification of these cells in the normal and neoplastic mammary gland and the lack 
of investigation of immunohistochemical changes from an epithelial to a mesenchymal 
phenotype  were the aims of a parallel research  started in 2012, and which has been included 
in the present report. 
In addition, another study  has been developed concerning CD117, a membrane-associated 
tyrosine kinase growth factor receptor encoded by C-Kit gene (Yarden et al., 1987). CD117  
is expressed in various cell types during embryonic development, it promotes different 
functions of cells and has been shown to be expressed by neoplastic cells as well (Ronnstrand, 
2004). Investigating mammary tumours, we noticed that only few studies had focused on the 
expression of CD117, on the difference  in  expression between normal tissue and neoplastic 
benign or malignant change in canine mammary tissue (Sailasuta et al., 2008). Since c-Kit is a 
proto-oncogene that encodes a transmembrane tyrosine kinase growth factor receptor and 
stimulates cell proliferation, it plays a crucial role in determining the existence of a correlation 
between c-Kit expression and Ki67 index (Thompson et al., 2011). Therefore, it was decided 
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to further deepen the knowledge in order to to characterize the immunohistochemical staining 
of CD117 in normal and neoplastic mammary tissue of the dog, and to correlate CD117 
immunohistochemical results with mammary histotype, histological stage (invasiveness), 
Ki67 index and patient survival time. 
The reader of this paper will find the findings acquired in the three years 2011-2013, which 
have been published or presented to national and international meetings.  
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2. SOME INFORMATION ABOUT BREAST CANCER 
Molecular taxonomy 
The changes in gene expression patterns, using complementary DNA microarrays, provided a 
distinctive molecular portrait of each tumour (Perou et al, 2000). Sets of co-expressed genes 
were identified for which variation in messenger RNA levels could be related to specific 
features of physiological variation. The tumours were classified into subtypes distinguished 
by pervasive differences in their gene expression patterns of mammary epithelium (Perou et 
al, 2000). Based on those differences four subtypes were identified:  
- Luminal like/ER+ (Estrogen Receprtor): so called because of the expression of many 
genes is expressed by the luminal cells. 
-  C-erb-B2: c-erbB-2 overexpression gene.  
- Basal like: expression of a clusters of gene proper of the basal epithelium. 
- Normal breast: overexpression of basal epithelium gene and low expression of genes 
of the luminal epithelium. 
Subsequently, Sorlie et al. (2001) modified the molecular classification, in search for 
correlations between gene expression patterns and parameters of clinical relevance, such as 
the survival rate and the likelihood of recidivism, thus demonstrating the prognostic value of 
this subtyping. Two major branches of subtypes were obtained: ER- and ER+ (luminal). The 
ER- cluster included the basal-like subtype (characterized by high expression of cytokeratin 5 
and  laminin 17 binding fatty acids), the c-erbB-2 subtype (characterized by a wide expression 
of genes in the segment c-erbB-2), and the normal group breast-like (which showed the 
expression of genes typical of adipose tissue and other non-epithelial cell types) (Sorlie et al., 
2001). These three clusters exhibited a remarkable expression of genes of the basal epithelium 
and a reduced or no expression of genes of the luminal epithelium. The second main group, 
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ER+, obtained from the analysis included three hierarchical sub- expressing genes typical of 
luminal epithelium, such as luminal A (high gene expression of ERα), luminal B and C 
(moderate expression of specific genes of luminal epithelium). In particular, the luminal C 
subtype was distinct from the other two luminal types for the expression of a set of genes 
whose function was unknown. The gene expression pattern represent the tumour biology, 
reflecting the biological diversity and correlate the different tumours with the clinical 
genomics was thought to be the key to understand this diversity (Sorlie et al., 2001). 
Further refinement for molecular phenotyping was given by Sorlie et al. (2003) in a 
subsequent study, thanks to the increasing in number of tumour cases, from 115 to 534, and to 
the use of intrinsic genes. The modified molecular phenotypes classification came to the 
number of subtypes known at present: basal-like, c-erbB-2 overexpressing, two luminal-like 
(A and B) and normal-like (Sorlie et al., 2003). The existence of different subtypes of breast 
cancer was confirmed by protein expression patterns assessed by immunohistochemistry 
(IHC) on tissue microarray (TMA), an efficient and reliable platform for subclassifying breast 
cancers into relevant subtypes, using a limited number of markers (Matos et al., 2005). In 
particular, the panels encompass at least anti- estrogen receptor (ER), anti-progesterone 
receptor (PR), anti- c-erbB2 and antibasal cytokeratin antibodies (CK 5/6 and 14) (Cheang et 
al, 2008; Kim et al., 2006). The obtained new classification was therefore, constituited by  
two hormone (estrogen (ER) and/or progesterone (PR) receptor positive types [luminal A (ER 
and/or PR+, c-erbB-2−), luminal B (ER and/or PR+, c-erbB-2+)], and three hormone receptor 
negative [c-erbB-2 overexpressing (ER/PR−, c-erbB-2+), basal-like (ER/PR−, c-erbB-2−, 
CK5/6 and/or CK14 and/or p63+), and normal-like (ER/PR−, c-erbB-2−, CK5/6 and/or CK14 
and/or p63−)]. Even if much has been learned in the last few years about the molecular 
taxonomy, it is still in evolution and likely to change over the coming years (Cummings et al., 
2011).  
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Prognostic value 
Breast cancer outcome in women varies widely and prognosis is determined by the pathologic 
examination of the primary carcinoma and the axillary lymph nodes. In 2002 the American 
Joint Commitee on Cancer (AJCC) identified six major prognostic factors that were 
recognised as strongest predictors of death. The major prognostic factors were: 
 Invasive carcinoma versus in situ disease. By definition, in situ carcinoma is confined 
to the ductal system and cannot metastatize while invasive carcinoma usually locally 
or distantly metastatize. 
 Distant metastases. Cure is unlike, especially in hormonally responsive tumours and 
the type of tumour influences the timing and location of metastases. 
 Lymph node metastases. In absence of distant metastases, it is the most important 
prognostic factor for invasive carcinoma. Approximally 10% to 20% of women 
without axillary lymph node metastases have a recurrence outside  the breast and 
about the same number die from breast cancer. In these patients, metastasis may occur 
via the internal mammary lymph nodes or hematogenously. 
 Tumour size. The size of a an invasive carcinoma is the second most important 
prognostic factor. The risk of axillary lymph nodes metastases increases with the size 
of the primary tumour, but both are indipendent of prognostic factors. 
 Locally advanced disease. Carcinomas invading into skin  or skeletal muscle are 
usually large and may be difficult to treat surgically. 
 Infllammatory carcinoma. Particularly poor prognosis is related to breast cancer 
presenting  with breast swelling and skin thickening due to dermal lymphatic 
involvement. 
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In addition to the six major factors used by the AJCC, a number of other factors have 
become increasingly important as predictive of outcome. 
 Histologic Subtype. The survival rate of women with special type of invasive 
carcinomas (tubular, mucinous, medullary, lobular, and papillary) is greater than 
60%, compared with less than 20% for women with non special type. 
 Histologic grade. The commonly used grading system, the Nottingham Histologic 
Score, combines nuclear grade, tubule formation and mitotic rate to classify 
invasive carcinomas into three groups that are highly correlated with survival.  A 
higher survival for patients with well-differentiated grade 1 carcinoma, and,  in 
contrast, most deaths  for poorly differentiated grade 3 carcinomas. 
 Estrogen and progesteron receptors. Immunohistochmistry assays are currently 
used to detect nuclear hormone receptors. This latter  finding is correlated with a 
better outcome and is an important predictor of response to hormonal therapy. 
 C-erbB-2. Its overexpression is associated with poor survival, but its main 
importance is as a predictor of response agents that target this transmembrane 
protein (trastuzumab or lapatinib). 
 Lymphovascular invasion. The presence of tumour cells within vascular spaces is 
strongly associated with the presence of lymph node metastases. It is a poor 
prognostic factor for overall survival in women without lymph node metastases 
and a risk factor for local recurrence. 
 Proliferative rate. Carcinomas with high proliferation rates have a poorer 
prognosis but may respond better to chemotherapy. The rate can be measured by 
mitotic counts or by immunohistochemical detection of cellular protein produced 
during the in cell cycle (ki-67). 
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 DNA content. Tumours with abnormal DNA indices have a slightly worse 
prognosis. 
 Response to nonadjuvant therapy. Pathologic response to chemotherapy can be 
used as a short-term end point for clinical trials 
 Gene expression profiling. Expression profiling has been shown to predict survival 
and recurrence-free interval, and also identifies patients who are most likely to 
benefit from particular types of chemotherapy (Robbins and Cotran, 2010) 
Standard clinical prognostic factors, such as patient age, tumour size, lymph node status, 
tumour grade, hormone receptor status or c-erbB-2 provide valuable information on the risk 
of recurrence; however, these estimates of clinical risk are coarse. On the contrary, multigene 
classifiers have the potential to complement traditional methods through provision of 
additional biological prognostic and predictive information in presently indeterminate risk 
groups (Rakha and Ellis, 2011). Indeed, the different molecular subtypes have been associated 
with different prognoses
 
(Sorlie et al., 2003), treatment planning
 
(Carey, 2011),  metastatic 
sites (Fountzilas et al. 2012; Gabos et al. 2006) and survival rates (Blows et al., 2010). Sorlie 
et al. (2001), based on a study of 49 patients with locally advanced disease status but without 
systemic metastases, conducted a survival analysis correlating ther subtypes with the overall 
survival rate and recurrence-free interval  . The recurrence-free interval  was defined as the 
interval between the date of breast surgery and the date of subsequent diagnosis of breast 
cancer. The overall survival rate is defined as the interval between the date of breast surgery 
and the date of death, related to breast cancer (Sotiriou et al., 2003). The added value 
identified by Sorlie et al. (2001) gave a clinical significance to these tumour subtypes, 
demonstrating a low survival rate and a high relapse rate for the Basal-like and c-erB-2+ 
subtypes, accompanied by a poor prognosis, with a high frequency of mutation in the TP53 
gene and amplification of the c-erbB-2 gene, respectively. The luminal presented a more 
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favorable prognosis than the previous   but with different outcomes between luminal A and B. 
The latter showed a worse outcome than the first (Sorlie et al., 2001).  
The molecular processes  at the basis of tumour progression have not been fully characterized 
as well as the factors that determine the metastatic potential of a tumour, both to the 
respective regional lymph node or to distant sites. A common hypothesis argues that the 
metastatic process is affected by the molecular changes that  evolve within few clones of the 
primary tumour that metastasize. If this were true, the metastasizing ability of  a small 
proportion of the primary tumour clones could not be predicted by the analysis of the primary 
tumour. An alternative hypothesis argues that the metastatic capacity is largely determined by 
the sum of the molecular changes that characterize the majority of cells in the primary 
tumour. In this case, the metastases could be predictable. The status of the regional lymph 
node, determined at the time of diagnosis, may represent a functional, even if imperfect 
surrogate of the process of metastasis. Lymph node metastases reflect the biological 
properties of the tumour (eg, motility, invasiveness) (Lu et al., 2008). 
The concept that the molecular information of the primary tumour may help    define the 
metastatic potential was investigated by Lu et al. (2008). Their formulated models, 
constructed on the basis of gene expression data, demonstrated predictive accuracy to 
biological characteristics, such as the status of ER, c-erbB-2, and tumour grade. Instead, the 
model failed to demonstrate the predictive accuracy to anatomical features such as lymph 
node status, tumour size and lymph-vascular invasion. The authors concluded by saying that 
the regional metastases develop in relation to time and to a "propensity" that could be due to 
inherent biological differences, best reflected by molecular subtypes, and that their prediction 
is of limited value (Lu et al., 2008). 
A further merit that was given to the molecular analysis methods was  the possibility to 
establish the preferential sites of distant metastases in association with different molecular 
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subtypes. It was found that bone metastases were more consistently associated with the 
luminal subtypes, less frequently  with the basal phenotypes. The opposite was true for 
metastases to the lung and brain, with no specific correlation between lung metastases and 
luminal A type. The pleural metastases were found almost exclusively in the luminal subtypes 
(Smid et al., 2008).  The ability of the tumour to head, survive and proliferate in certain 
distant organs requires a different set of genes, as well as the ability of the tumour to 
metastasize.  A lot of genes differentially expressed were identified, many of which were 
common among the subtype and the site in which the subtype  had preferentially 
metastasized; wingless-type MMTV integration site family (WNT) signalling was up-
regulated in the basal subtype as well as in its specific brain metastasis. The five molecular 
subtypes are therefore clearly different with regard to their ability to metastasize to different 
body sites (Smid et al., 2008). 
The profile of gene expression is thus a most powerful predictor of the outcome of the 
disease, than traditional systems based on clinical and histological criteria (van de Vijver et 
al., 2002).  
Target therapeutic and predictive approach 
While prognostic factors intend to objectively predict the clinical outcome independently 
from treatment, the predictive approaches are intended to predict the response of patiens to 
specific therapeutic therapies and are also associated with tumour sensitivity or resistance to 
therapy (Weigel et al., 2010). 
The discovery of molecular subtypes of breast cancer gave a further proof of the fact that 
biological diversity consequently denies a unique therapeutic approach (Peppercorn et al., 
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2008). The therapeutic approach to breast cancer varies according to the different molecular 
phenotypes. 
The luminal subtypes are hormone receptor-positive, therefore appropriate for endocrine 
therapy with tamoxifen combined with chemotherapy (Peppercorn et al., 2008). This is 
especially true for the luminal A, in which conversely only a small amount of those tumours 
respond to classical chemotherapy. The luminal B, also referred to as triple positive for the 
expression of c-erbB-2 as well as hormone receptor, is often responsive to chemotherapy 
(Robbins and Cotran, 2010). 
The expression of ERα is lately undoubtedly considered the most important biomarkers in 
breast cancer, because it provides an index of sensitivity to endocrine treatment (Weigel and 
Dowsett, 2010).  
The therapeutic approach to c-erbB-2-overexpressing phenotypes is by treating patients with 
chemotherapy, and c-erbB-2 targeted therapy such as trastuzumab (Carey, 2011).  
The c–erbB-2 overexpressing phenotypes, besides being a predictor factor of resistance to 
endocrine therapy or selective resistance to tamoxifen predicts resistance to some 
chemotherapies (Harris et al., 2007).  
The therapeutic approach to basal-like and normal-like phenotypes represent today  a huge 
challange since they are not responsive to hormone therapy, but they are treated with 
chemotherapy alone
 
(Carey, 2011; Matos et al., 2005). Treatment of these phenotypes only 
with chemiotherapy implies an estimate of the residual risk of 30-40% (Fig. 1) (Carey, 2011). 
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Fig. 1: Estimate residual risk 
 
Adjuvant therapy for breast cancer in the initial state, with the initial risk of recurrence of approximately 60%. If 
the patient present a tumour hormone receptor positive phenotype, she will be treated with endocrine therapy and 
chemotherapy, with a subsequent residual risk of recurrence <25%. In case of c-erbB-2 overexpressing 
phenotype (c-erbB-2+), the patient will be treated with anti- c-erbB-2 therapy in addition to chemotherapy, with 
estimates residual risk of <25%. If the cancer present a triple negative phenotype the treatment is chemotherapy 
only, with residual risk> 30-40% (Modified from Carey, 2011). 
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3. PHENOTYPIC CONCORDANCE AND DISCORDANCE BETWEEN 
PRIMARY MAMMARY CARCINOMA AND ITS RELATED 
METASTASES 
The study by  Weigelt et al. (2003) supported the concept that the ability to metastasize to 
distant sites is a  genetic properties of breast carcinomas. Shown that the gene expression 
profile of the primary tumour is closely similar in distant metastases of the same patient, 
indicative of the hypothesis that the ability of the metastatic breast cancer is an innate 
characteristic and it is not based on a clonal selection (Weigelt et al., 2003).  
Previously, Fidler et al. (1977) found that clones, obtained in vitro from a parental malignant 
melanoma murine cell culture, varied greatly in their ability to produce metastatic colonies. 
This involved the striking conclusion that the sub-cell population having highly metastatic 
power pre-existed in parental population (Fidler et al., 1977). This model implies that 
metastases arise from a sub-clone, which  could be molecularly distinct from their primary 
tumour. The Fidler clonal concept is widely accepted, although the metastatic process has also 
been described as a stochastic event, having the primary tumour cells with equal metastatic 
potential (Weigelt et al., 2003; Milas et al., 1983). 
Many human tumours develop through a succession of genetic and epigenetic changes that 
confer to the cells neoplastic characteristic. This process can be likened to a Darwinian 
evolution within the microcosm of living tissues, in which individual cells represent the 
selection unit. Single cells that possesses advantageous characteristics (such as survival and 
proliferation) are selected to become the progenitor of a successor cell population that 
eventually will dominate the tumour mass. The initiator of the next round of successors clones 
represent a rare variant that arises between the many successor cells. About 6-10 cycles of 
clonal sequences are needed to generate highly malignant tumour cells. A different model of 
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metastatic mechanism relies on the fact that the tendency to metastasize is largely determined 
by the identity of the mutant alleles, which are acquired relative at the beginning of the 
various carcinogenesis stages (Bernards et al., 2002). 
In order to investigate the molecular differences between the primary tumour and metastases 
Ramaswamy et al. (2003) compared the gene expression profile of metastatic adenocarcinoma 
form multiple tumour phenotypes with not corresponding primary adenocarcinomas. They 
proved that a part of primary tumours resembled the metastatic ones regarding the gene 
expression signature (Ramaswamy et al., 2003). 
Weigelt et al. (2005), studying the gene expression profile of a set of 70, already proved to be 
efficacy in predicting the metastatic potential, found that distant metastases reflect the 
molecular subtypes and prognostic signature (70 genes) of their primary tumour. These results 
support the hypothesis that the molecular subtypes originate from different cell types within 
the mammary gland and thus reflect the different biological entities, which are kept in the 
metastatic process (Weigelt et al. 2005).  
Divergent results were deduced from a study of Aitken et al. (2010), which carried out 
changes in expression through quantitative analysis of ER, PR, c-erbB-2 in primary mammary 
site tumour and its related lymph node metastasis. Given that nodes are excised in standard 
surgical practice, as sentinel node biopsy, axillary node sample, or node clearance, and 
assessed by a pathologist for routine staging, the authors showed that there may be added 
benefit to molecular testing on nodal metastases as well as the primary tumour in order to 
guide adjuvant therapy. While this might incur additional financial costs for specimen 
processing and molecular analysis, savings could be made by avoiding overtreatment. The 
authors demonstrated that a significant number of patients showed a quantitative difference in 
expression of the molecular markers between primary tumour and lymph node metastasis and 
this data may confer increase therapeutic sensitivity or resistance to targeted therapy. 
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Therefore, the difference in receptor expression levels may be one of the causes of treatment 
failures, found in some clinical cases and the phenotyping of both primary and lymph node 
would reduce morbidity for patients and ultimately has the potential to produce more 
favourable clinical outcomes (Aitken et al., 2010). 
In conclusion the different studies regard the comparison between the phenotypes of primary 
site and lymph node metastasis have highlighted the existence of a concordance in which the 
primary tumour and the lymph node metastasis have the same phenotype, and a discordance 
with differences in phenotype between primary and metastases. On the basis of this 
knowledge, the future treatment decisions should be based on the gene expression profile of 
both the primary tumour and its related lymph node metastasis (Aitken et al., 2010).  
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4. MOLECULAR PHENOTYPES IN CANINE MAMMARY TUMOURS 
Mammary tumours are among the most common tumour in dogs, in fact, they represent 25–
50% of all neoplasms in this species, with an average age of occurrence between 6 and 10 
years (Millanta et al., 2005a). 
The high homology between the canine and the human genomic sequence, as the many 
similarities regarding the morphology, biological behavior, and clinical course of  mammary 
tumours, is the starting point for the study of comparative pathology that is proposing the dog 
as a valuable comparative and predictive model for human breast cancer. Recent studies have 
shown that the general basic biology of cancer in dogs such as tumour establishment and 
metastatic progression is similar to what happens in human cancer (Pinho et al., 2012). Most 
of the cancer-associated genetic alterations (Fig. 2) that are known to play a role in mammary 
tumour development and progression are similar in both species (Rivera et al., 2011).  
A recent study demonstrated that many genes deregulated in human breast cancer were also 
found deregulated in canine mammary tumours compared with normal mammary tissue. This 
first genome-wide comparative analysis demonstrated that the pathways showing 
upregulation in tumour from both species are those related to increased proliferation activity, 
whereas the pathways related to cell development, cell matrix adhesion, and cell 
communication are downregulated. Furthermore,  it has  also been shown  a great degree of 
homology between human and canine mammary tumours in the perturbation of many cancer 
related pathways (Uva et al., 2009). The genome similarities of dogs and humans support 
strongly the genetic homology between both species (Pinho et al., 2012). 
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Fig. 2: Comparative analysis of the role of the critical genes and signaling pathways involved in the 
carcinogenesis of human breast cancer and canine mammary tumour 
 
The first study regarding the gene expression of mammary tumours was accomplished by Rao 
et al. (2008) who characterized, with the use of the cDNA microarray, the expression profile 
of three different cell lines of canine mammary carcinoma originating from histologically 
distinct primary tumours: 
- CMT (Canine Mammary Tumour) - U335 (histological type osteosarcoma) 
- CMT- U229 (atypical benign in mixed tumour histological type) 
- P114 (anaplastic histological type carcinoma) 
The evaluation of the gene expression profile of the cell lines showed correspondence with 
the tumour of origin and the differential regulation of several pathways such as the WNT, 
integrins, cell cycle, alternative complement cascade, cytokine/Rho-GTPase. These pathways 
showed overlaps with those found in humans, therefore the expression profile of spontaneous 
canine mammary carcinomas was supposed to act as a biological sieve for the identification 
of pathways or of gene expression profiles that are involved in carcinogenesis (Rao et al., 
2008). The highlighting of molecular subtypes of canine mammary tumours by using gene 
expression patterns of a intrinsic gene set, similarly to what was done in humans, has not been 
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performed in veterinary medicine because of a reduced representation of similar genes on the 
canine microarray (Rao et al., 2008). 
The new classification of distinct molecular phenotypes was developed by Sarli et al. (2007) 
using an immunohistochemical panel with anti-cytokeratin 19 (CK19), -CK14, -CK 5/6, -ER, 
-PR, -vimentin, -c-erbB-2, in order to identify the following phenotypes: 
• luminal -like (CK19+, ER+/-, PR+/-, CK14-, CK5/6-) type A (c-erbB-2-) and type B (c-
erbB -2+); 
• basal- like (CK19-, ER-, PR-, CK14+, CK5/6+, c-erbB-2-); 
• c-erbB-2+ (CK19-, ER-, PR-, CK14-, CK5/6-, c-erbB-2+). 
The subtypes luminal A and luminal B showed the same phenotype but differed in the 
expression of c-erbB-2, which is considered an important prognostic index  of tumour 
progression in canine mammary tumours as well as in woman breast cancer. The 
myoepithelial proliferation, in complex and in mixed tumour, resulted negative for 
myoepithelial cells markers (CK14 and CK5/6), which characterize the basal- like phenotype, 
but were positive for vimentin. The positivity for cytokeratins was expressed only when the 
cells were surrounded by the myoepithelial luminal counterpart. Sarli et al. (2007) suggested 
that the above mentioned data could be indicative of lack of specific phenotypes in canine 
pathology or of the need to investigate further for myoepithelial markers. 
On the basis of the immunohistochemical panel proposed by Matos et al. (2005), Gama et al. 
(2008) characterized 102 canine mammary carcinomas based on the immunohistochemical 
panel which involved the evaluation of five molecular markers (ER, c-erbB-2, CK5, p63 and 
P-cadherin). ER and p63 positive cases showed the characteristic nuclear staining, whereas 
those positive for CK5 showed a cytoplasmic pattern. The c-erbB-2 positive tumours to have 
presented a membranous staining, P-cadherin positive tumours showed both a cytoplasmic or 
a membranous staining. The tumour classification was effected on the basis of ER and c-
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erbB-2 status, in accordance with the algorithm formulated by Nielsen et al. (2004); positive 
tumours to ER were classified as luminal, distinguishing them further into A and B on the 
basis of negativity or positivity to c-erbB-2, respectively. Tumour that did not express ER, but 
were positive for c-erbB-2 were defined as c-erbB-2 overexpressing phenotype, or those cases 
that continued to be negative but positive for basal markers CK5, p63, and P-cadherin  were 
classified as basal. Tumours that did not express any markers were identified as “none 
phenotype”. CK5, p63 and P-cadherin are proteins that are expressed early in epithelial 
differentiation and may contribute to a committed stem cell and/or progenitor phenotype 
(Boecker and Buerger, 2003; Boecker et al., 2002). In the study by Gama et al. (2008), the 
authors demonstrated that these markers were upregulated in the basal subtype, similarly to 
the previous results  by Matos et al. (2005). In fact, the basal subtype rarely expressed just 
one basal marker but frequently expressed them simultaneously, which suggested a more 
undifferentiated profile. C-erbB-2 overexpressing subtype was also characterised by an up-
regulation of basal markers, confirming some human breast studies, which suggested that c-
erbB-2-overexpressing tumours should be included in a bona fide basal-like subclass (Gama 
et al., 2008; Matos et al. 2005). In contrast, the majority of luminal tumours in Gama et al. 
(2008) series were simultaneously negative for basal cell markers, with some cases showing 
basal marker expression, which was also described by some authors who reported co-
expressing basal CK and hormone receptors or c-erbB-2. 
The correlation between subtypes obtained and histology showed that ER positive luminal A 
tumours more frequently associated with complex tumour type, low histological grade, less 
invasive and low proliferative tumours (Gama et al., 2008; Sorlie et al., 2003), whereas basal-
like and c-erbB-2 overexpressing subtypes were associated with simple and carcinosarcoma 
tumour types, high histological grade, lymphovascular invasion and high proliferation, 
 33 
 
 
features that are in accordance to the ones described in human literature for basal-like cancers 
(Gama et al., 2008; Kim et al., 2006; Matos et al., 2005; Sorlie et al., 2001).  
In terms of prognosis, it is already well known that molecular phenotypes are associated with 
different clinical outcomes in canine mammary tumours as well as in human tumours  (Gama 
et al., 2008; Sorlie et al., 2003). Basal subtype is associated with lower survival rates and 
appearence of recurence, similarly to human breast cancer studies. In contrast to basal 
subgroup, luminal and c-erbB-2 overexpressing subtypes show increased survival rates. 
The fact that luminal tumours were associated with a better prognosis is not surprising since 
ER positive human breast carcinomas are usually associated with a more favourable clinical 
outcome. In veterinary pathology, however, the prognostic value of ER in canine mammary 
cancer is still a matter of debate. C-erbB-2 overexpressing tumours were found usually 
associated with established indicators of poor prognosis such as large tumour size, high 
histologic grade, invasion, simple histologic type and high proliferative indices (Gama et al., 
2008; Rakha et al., 2006; Sorlie et al., 2008). However, Kaplan–Meier analysis in the study 
by Gama et al. (2008)  revealed that  C-erbB-2 subtype was related with a more favourable 
clinical outcome, findings that were in contrast with human studies, which describe similar 
survival rates for c-erbB-2 overexpressing and basal-like subtypes (Gama et al., 2008; Rakha 
et al., 2006: Sorlie et al., 2008). 
In order to evaluate the prognostic potential of the hormone receptors expression in canine 
malignant mammary tumours, Chang et al. (2009) conducted a study on benign and malignant 
tumours. The expression of ER and PR was significantly more frequent in benign tumours 
compared to the malignant counterpart. Moreover,  among the malignant samples only those 
expressing ER and PR had a high survival rate, compared with malignant tumours expressing 
ER but not PR suggesting, therefore, that the PR could be considered as an important 
prognostic factor (Chang et al., 2009).  
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It is known that malignant tumours negative to PR receptors have a higher proliferation index 
compared to those PR+, suggestive of the fact that the progression to malignancy in 
spontaneous mammary tumours was  accompanied by a decrease in the dependence hormonal 
steroid (Geraldes et al., 2000). 
In the study by Millanta et al. (2005), the expression pattern of canine steroid receptors 
showed that ER expression is significantly high in the normal tissue, in hyperplastic and 
dysplastic lesions, and in benign tumours, but significantly lower in carcinomas. There were 
not apparent significant changes in the reactivity of PR in normal tissue, dysplastic and 
benign neoplastic lesions except for  a significant reduction of expression in carcinomas. The 
absence of ER and PR only in the  female dog is associated with a high mortality rate and 
these data confirm previous observations that demonstrated that canine mammary tumours 
have features in common with hormone-dependent human breast cancer (Millanta et al., 
2005a) 
The immunohistochemical investigation of ER in canine mammary tumours was found to be a 
simple application technique with prognostic value that could be useful for appropriate 
hormonal therapies selection (Nieto et al., 2000). 
With regard to the prognostic value of c-erbB-2, studies present in literature reported 
controversial data, in spite of what is known  in the woman. According to Hsu et al. (2009), 
the relationship between the clinical course and the protein expression of c-erbB-2 in dogs 
with malignant mammary tumour indicated a greater overall survival rate in c-erbB-2 
overexpressing tumours compared to those with normal levels of the antigen. The reason for 
such a difference between c-erbB-2 overexpressing phenotype in canine and in women breast 
cancer remained unclear for the authors. Certainly c-erbB-2 seemed to play an important role 
in tumour formation, but did not seem to be directly correlated with the progression to 
malignancy (Hsu et al., 2009). Given the high expectation of suraival rate in canine mammary 
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c-erbB-2+ tumours, the role of this protein in oncogenesis may be different from that played 
in breast cancer (Hsu et al., 2009).  
Opposite results results exerted that c-erbB-2+ tumours were correlated with indicators of 
poor prognosis, such as tumour size >3cm, histological grade III [presence of neoplastic 
emboli (Gilbertson et al., 1983)], type of invasive growth, absence of hormone receptors and 
a period of <6 months without relapse after surgery. Those results were in agreement with 
what has been observed in the human, having characteristics indicative of a worse prognosis 
(Martin de las Mulas et al., 2003; Sorlie et al., 2003). 
Mammary tumours in the dog are characterized by significant high molecular heterogeneity, 
thereby not surprising that individual markers could not accurately estimate the heterogeneity 
of breast cancer (Rakha et al., 2009) and that, on the contrary, could benefit from a 
classification based on their molecular differences. 
Sassi et al. (2010)  applied an immunohistochemical panel (anti –ER, -PR, c-erbB-2, -CK5/6 
and -CK14)  to a series of canine mammary carcinomas in order to: identify molecular 
phenotypes based on a modified molecular classification, find  possible correlation between 
the phenotypes and stage and histological grade, and use  the phenotypes as a prognostic aid 
in veterinary practice. The molecular phenotypes have been identified in accordance with the 
flowchart classification proposed by Conforti et al. (2007) (Fig.3).  
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Fig. 3: Flowchart classification based on Sassi et al. (2010) 
 
 
Out of 45 samples, the panel of antibodies has identified only three tumour groups (luminal 
A, luminal B and Basal-like) out of the five groups known in Human Medicine (Sassi et al., 
2010) and still different from the four identified (luminal A and B, Basal-like, c-erbB-2 
overexpressing) found  by Gama et al. (2008). The uses of different panels and criteria to 
define markers positivity  was probably the cause of the differences found between Gama et 
al. (2008) and  Sassi et al. (2010) studies. Sassi et al. (2010) demonstrated a correlation 
between the molecular based classification and the histological grade, but they did not find a 
relation between the stage and the morphological classification of tumours. In addition,  
luminal A phenotype included a high percentage of grade I tumour, compared to  luminal B in 
which prevailed grade II and III tumours. On the contrary, Gama et al. (2008) showed that 
only the basal-like phenotype was correlated with  grade and vascular invasion. Sassi et al. 
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(2010) did not detect any similarity between the molecular classification system and survival 
rates, while Gama et al. (2008) found only for the basal phenotype the association with short 
survival. 
In multivariate analysis, according to Sassi et al. (2010), staging and histological grade 
showed an independent association with survival rate, while the phenotypes and the 
histological types did not show any association. These data suggested that caution should be 
used  when applying the new classification system for canine mammary tumours, in which the 
fundamental prognostic information derived from the staging and histological grade (Sassi et 
al., 2010). 
Canine mammary tumours have been treated in different ways with surgery as the first choice 
of therapy, either alone or in combination with chemotherapy (Lana et al., 2007) even though 
no standard therapeutic protocols are available
 
(Lavalle et al., 2012). Receptor evaluation 
has been introduced to use an anti-estrogen therapy, whose side-effects include endometritis 
in female dogs  with ER negative tumours (Morris et al., 1993) 
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5. MOLECULAR PHENOTYPES IN FELINE MAMMARY TUMOURS 
Mammary tumours are common in female cats, especially in older animals, and the 
majority of them are malignant and very aggressive (MacEwen and Withrow 1996; 
Multon, 1990). Feline malignant tumours grow rapidly, and metastases are reported to occur 
in 50–90% of affected animals (Hayden and Nielsen, 1971). Metastasis to regional lymph 
nodes (83%), lungs (83%), pleura (22%) and liver (25%) are most common. However, 
various studies have also documented widespread metastases to the adrenal glands, 
diaphragm and kidneys (Giménez et al., 2010). 
Nowadays, the most important prognostic factor in cats with mammary gland neoplasia is 
tumour size, which significantly affects both disease-free interval and survival time (Lana 
et al., 2001). Other important prognostic factors are: 
 histopathologic grade: An association between survival time and histopathologic 
grade has been demonstrated. The rate of death 1 year after surgery was 0% in cats 
with well-differentiated carcinoma, and 100% in those with poorly differentiated 
carcinoma. However, there was not a good correlation between moderate 
differentiation and survival time (Jeglum et al., 1985);  
 mitotic rate: The number of mitotic figures found in tumour tissue has been shown 
to be of prognostic value. Longer survival times were seen in animals with 
tumours exhibiting fewer than two mitotic figures per high power field (Weijer et 
al., 1983); 
 disease stage: Clinical stage at presentation has been shown to be significantly 
associated with survival time (Ito et al. 1996); 
 surgical approach: In a study of cats  bearing malignant mammary 
adenocarcinoma,  which had undergone radical mastectomy,  a significantly 
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reduced rate of local recurrence was compared with cats that had undergone 
conservative surgery (MacEwen et al., 1984); 
 molecular markers: The expression of some genes, receptors or proteins can be 
altered during the malignant process in feline mammary tumours. These so-called 
molecular markers can be detected by immunohistochemistry and yield useful 
prognostic information in some cases (Giménez et al., 2010). Most studied markers 
are: hormone receptors ER and PR (Millanta et al., 2006), c-erbB-2 (Millanta et 
al., 2005b), cyclin A, protein p53, macrophage-stimulating protein receptor 
(RON), vascular endothelial growth factor (VEGF), cyclo-oxygenase (COX) and 
topoisomerase IIβ binding protein 1 (TopBP1) (Giménez et al., 2010). 
 Regarding the hormone receptors state, Martín de las Mulas et al. (2002) demonstrated 
through the analysis of the immunohistochemical expression of PR receptors in normal, 
dysplastic and neoplastic mammary glands of cats that benign mammary lesions, like those in 
dogs, appeared to have higher PR receptor profiles than mammary carcinomas, with 66.7% of 
benign tumours and dysplasias and 37.5% of malignant mammary lesions being progesterone 
receptor positive. The elevate percentage of feline PR+ tumours carcinomas suggested the 
possible role of PR as an early promoter of tumour growth in the cat (Millanta et al., 2006). In 
2000, Martín de las Mulas et al. consided the expression of ER, detecting significant decrease 
in ER positivity between normal and dysplastic tissues and invasive carcinomas. It has been 
suggested that steroid hormones may play a role in promoting cellular proliferation in the 
early stages of development of canine mammary tumours (Rutteman, 1990). Cellular 
proliferation has been recognised as a prognostic indicator in ER−human breast carcinomas, 
whereas benign mammary lesions in both cats and dogs (Rutteman et al., 1993) had higher 
ER profiles.  Estrogens might act by binding ER normally present in epithelial and stromal 
cells of mammary gland inducing in these cells an increased expression of PR receptors. In 
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this hypothesis the un-reactivity of epithelial and stromal cells for ER could be explained with 
a previous presence of ER in these tissues in the initial stage of the diseases and a progressive 
loss during the evolution of the disease (Millanta et al, 2005a). The high negative rates of ER 
expression seem to be a characteristic feature of feline mammary carcinomas when compared 
with human and canine tumours and suggest a lack of estrogen dependency as previously 
proposed. Also, the reduced percentage of ER+ invasive carcinomas demonstrate the behavior 
and phenotype of typically aggressive mammary tumour  in cats  (Martín de las Mulas et al., 
2000). The evaluation of ER receptors state in normal, dysplastic and neoplastic feline 
mammary tissue assumed a prognostic value as ER expression was significantly higher in 
normal and hyperplastic tissue more than in neoplastic tissue. In light of the correlation 
between the hormone receptors expression and the proliferation index obtained by 
immunolabeling with MIB-1 (Mouse Monoclonal IgG1),  ER+ phenotypes had a proliferation 
index significantly lower than ER- phentypes, having therefore a poorer prognosis (Millanta 
et al., 2006). Considering both estrogen and progesterone receptors,  feline mammary 
carcinomas showed features in common with hormone-independent human breast cancer 
(Millanta et al., 2005a) 
The feline c-erbB-2 was found to be barely detectable in normal mammary gland, increased in 
mammary benign tumours, and elevated in a high percentage in carcinomas. The correlation 
between c-erbB-2 overexpression and the overall survival rate showed that cats affected by c-
erbB-2 overexpressing phenotype tumours had shorter overall survival time. These findings  
suggested that c-erbB-2 status could provide valuable prognostic and predictive information 
(Giménez et al., 2010). The effect of c-erbB-2 overexpression in feline mammary tumours 
seemed to be more similar to human tumours than in those of the dog (Millanta et al., 2005b). 
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Treatment options that have been studied for feline mammary neoplasia are surgical exci-
sion, chemotherapy, immunotherapy and radiation therapy. These differ in terms of clinical 
outcome (Giménez et al., 2010; Lana et al., 2007). Regarding the chemiotherapy, a recent 
retrospective study on the use of adjuvant doxorubicin therapy after surgical excision in 67 
cats reported a Kaplan Meier median survival time of 448 days and called for randomized 
trials to prove the true efficacy of chemotherapy (Novosad et al., 2006).  
As for canine mammary carcinomas, also for queens no standard therapeutic protocols are  
available
 
(Lavalle et al., 2012)  
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1. MOLECULAR PORTRAIT-BASED CORRELATION BETWEEN 
PRIMARY CANINE MAMMARY TUMOUR AND ITS LYMPH NODE 
METASTASIS: POSSIBLE PROGNOSTIC-PREDICTIVE MODELS 
AND/OR STRONGHOLD FOR SPECIFIC TREATMENTS? 
 
Introduction 
Canine mammary tumour and human breast cancer are heterogeneous diseases commonly 
occurring in female dogs [1,2] and in women [3,4]. 
Traditionally, breast cancer has been classified by morphological criteria in both human [5] 
and veterinary [6,7] medicine. Recent veterinary attention, as widely explained in the general 
part regard canine mammary tumours, has focused on the protein expression profile and four 
main carcinoma subtypes have been identified [8,9]: luminal A, luminal B, c-erbB-2 
overexpressing and basal-like. Recently, molecular characterization in human breast cancer 
has also been applied to the metastasing lymph nodes [15]. The metastatic process is in fact 
the most urgent, important and difficult issue to approach in human [16] and animal cancer 
medicine. The relationship between the primary tumour and the lymph node metastasis from 
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the same patient was studied by Wu et al. [15] to determine if satellite tumour are uniform or 
divergent in molecular properties and to provide new information of diagnostic and 
therapeutic significance [16]. 
Recent publications emphasized several similarities between human breast cancer and canine 
mammary tumour, such as the relative age at onset, incidence, risk factors, biological 
behaviour, metastatic pattern, histopathological and molecular features, metastases-associated 
expression profile [17], and response to therapy [18,19]. 
The aim of this study was to analyze the relationship between the primary mammary tumour 
and its lymph node metastasis based on immunohistochemical molecular characterization to 
develop the most specific prognostic-predictive models and targeted therapeutic options. 
Methods 
Samples 
Specimens of mammary carcinomas from 20 female dogs were collected from the database of 
the Pathology Service of the Department of Veterinary Medical Science of Bologna 
University and from the Department of Animal Pathology of Pisa University.  
The 20 dogs comprised 11 mixed breed, two German Shepherd, one Yorkshire, two English 
Setter, two Doberman, one Maremma Shepherd and one Poodle. Dog ages ranged from six to 
14 years with a mean age of 10.3 and a median of 10.5. Two-year follow-up survival data 
were available for 11 out of the 20 animals with invasive carcinomas included in the study. 
Overall survival time was defined as the time from the day of diagnosis until the day of death 
or last follow-up. All the latest data are summarized in Table 1. 
Cases were selected based on both the primary mammary neoplasia and histological grade II 
(grade II: invasive carcinoma and metastases to regional lymph nodes) according to 
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Gilbertson et al. [25]. No cases displayed systemic metastases. Samples were available as 
sections stained with hematoxylin and eosin and obtained from formalin-fixed and paraffin-
embedded tissue block. 
Table 1: Individual data (Beha et al., 2012) 
 
Histological diagnosis and immunohistochemistry 
Histological diagnosis was made according to the WHO classification system [6]. Seven 
consecutive 4μm-thick sections were cut from the paraffin blocks containing representative 
tumour samples and labeled by immunohistochemistry with the following antibodies: anti-
ER, -PR, -c-erbB-2, -CK5/6, -CK14, -CK19, -p63. Data on the primary antibodies are 
summarized in Table 2. 
 53 
 
 
Table 2: Primary antibodies, resources and dilutions used in immunohistochemistry (Beha et al., 2012) 
ANTIBODY (−ANTI) CLONE MANUFACTURER DILUTION 
ER B-10 Abcam, Cambridge, UK 1: 300 
PR PR4-12 Oncogene TM, Boston, MA, USA 1: 100 
c-erbB-2 Polyclonal Dako, Glostrup, Denmark 1: 250 
Cytokeratins 5/6 D5/16B4 Zymed (South San Francisco, CA, USA) 1: 100 
Cytokeratin 14 Ab-1 (LL002) NeoMarkers (Fremont, CA, USA) 1: 300 
Cytokeratin 19 BA17 Dako (Glostrup, Denmark) 1: 50 
p63 4A4 Dako (Glostrup, Denmark) 1: 50 
 
Sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was blocked by 
immersion in H2O2 0.3% in methanol for 20 min. Sections were then rinsed in Tris Buffer 
and antigen was retrieved with citrate buffer (2.1 g citric acid monohydrate/liter distilled 
water), pH 6.0 (except for CK 5/6 which use EDTA, pH 8.0), and heating for two 5-min 
periods in a microwave oven at 750 W, followed by cooling at room temperature for 20 min. 
All antibodies were incubated with the tissue sections overnight at 4°C, and their binding was 
revealed by a commercial streptavidin-biotin-peroxidase technique (LSAB Kit, Dako, 
Amsterdam, The Netherlands). Diaminobenzidine (0.05% for 10 min at room temperature) 
was used as chromogen. Slides were counterstained with Papanicolaou's hematoxylin. 
As a negative control, the primary antibody was replaced with an irrelevant, isotype-matched 
antibody to control for non-specific binding of the secondary antibody. As positive controls to 
assess the cross-reactivity with canine tissues and the specificity of the immunohistochemical 
stain, sections of normal canine uterus (for anti-ER and -PR antibodies), canine skin (for anti-
CK5/6, -CK14, -CK19 and -p63 antibodies) were used following the same protocols. A 
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human poorly differentiated invasive ductal mammary carcinoma (kindly provided by P. 
Viacava, Department of Oncology, University of Pisa, Italy) known to react with c-erbB-2 
antibody was used as positive control. 
The staining result was classified semi-quantitatively with a dichotomous evaluation: positive 
or negative. The sample was considered positive: 
• when presenting cytoplasmic stain in more than 1% of the invasive tumour cells for 
anti-CK-19, CK-5/6 and anti-CK14 antibodies [26]; 
• when presenting complete membranous stain in more than 10% of tumour cells for 
anti- c-erbB-2 antibody according to the Hercept-test [27]; 
• when presenting nuclear stain in more than 5% of tumour cells for anti-ER and anti-
PR antibodies [28]; 
• when presenting nuclear stain in more than 10% of tumour cells for anti-p63 antibody 
[29]. 
Molecular taxonomy 
The application of the panel allowed cases to be grouped into five molecular subtypes 
according to an algorithm by Sassi et al. [9] modified as follows: 
• Luminal-A: ER+ and/or PR+, c-erbB-2–, regardless of CK5/6, CK14, p63 staining. 
• Luminal-B: ER+ and/or PR+, c-erbB-2+, regardless of CK5/6, CK14, p63 staining. 
• c-erbB-2 overexpressing: ER–, PR–, c-erbB-2+ regardless of CK5/6, CK14, p63 
staining. 
• Basal-like: ER–, PR–, c-erbB-2–, CK5/6+ and/or CK14+ and/or p63+. 
• Normal-like: Negative to all markers. 
Results 
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Diagnosis 
Eight of the 20 primary tumour were classified as simple tubulopapillary carcinomas, eight as 
solid carcinomas, two as complex carcinomas and two as anaplastic carcinomas. 
Immunohistochemistry and molecular phenotypes 
Immunohistochemistry for ER, PR, c-erbB-2, CK5/6, CK14, p63 in the primary tumour and 
in the respective lymph node metastasis is summarized in Table 3. In each case the epithelial 
origin of cancer was confirmed by CK19 staining. Based on the applied algorithm, molecular 
phenotypes were obtained in the primary mammary tumour and in their lymph node 
metastases (Table 4). Four phenotypes (luminal A (Figure 1A-B, line 1-2-3), luminal B 
(Figure 2A-B, line 1-2-3-4), c-erbB-2 overexpressing (Figure 3A-B), basal-like (Figure 4A-B-
C)) were diagnosed in primary tumour (eight (40 %), seven (35 %), two (10%), three (15%) 
respectively) and five (luminal A (Figure 1C-D-E, line 1), luminal B (Figure 2C-D-E, line 1), 
c-erbB-2 overexpressing (Figure 2C-D-E, line 2 and Figure 3c-d-e), basal-like (Figure 2c-d-e, 
line 3 and Figure 4c-d-e), normal-like (Figure 1c-d-e, line 3 and line 4 of Figure 2c-d-e)) in 
the lymph node metastases (five (25%), three (15%), four (20%), six (30%), two (10%) 
respectively). 
Relationship between molecular phenotype in the primary mammary tumour 
and its related lymph node metastasis 
Phenotypic concordance was found in 13 of the 20 cases (65%) (five luminal A (Figure 1, 
line 1), three luminal B (Figure 2, line 1), two c-erbB-2 overexpressing (Figure 3) and three 
basal-like (Figure 4)). Seven cases (35%) showed discordance with lymph node phenotypic 
profile differing from the primary tumour (two luminal A became basal-like (Figure 1, line 2), 
one luminal A became normal-like (Figure 1, line 3), two luminal B became c-erbB-2 
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overexpressing (Figure 2, line 2), one luminal B became basal-like (Figure 2, line 3), one 
luminal B became normal-like (Figure 2, line 4)) (Table 3). C-erbB-2 overexpressing and 
basal-like primary tumour were 100% concordant with the molecular phenotype of the 
respective lymph node metastases (Figure 3 and Figure 4). Luminal A and luminal B were 
concordant in 65.2% and 42.9% respectively of primary tumour for the same comparison. 
Table 3: Summary of immunohistochemical staining 
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Table 4: Molecular phenotypes 
 
Histological diagnosis in primary mammary tumour compared to molecular 
phenotypes and to concordance/discordance 
In the primary tumour the luminal A phenotype displayed a different histological tumour 
pattern, i.e. simple tubulopapillary (one case) (Figure 1A-B, line 1), solid (six cases) (Figure 
1A-B, line 2), anaplastic (one case) (Figure 1A-B, line 3). Luminal B phenotype displayed a 
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different histological tumour pattern, i.e. simple tubulopapillary (four cases) (Figure 2A-B, 
line 1 and 4), solid (two cases) (Figure 2A-B, line 2) and complex (one case) (Figure 2A-B, 
line 3). The c-erbB-2 overexpressing phenotype showed two patterns, i.e. tubulopapillary 
(one case), and anaplastic (one case) (Figure 3A-B). The basal-like phenotype displayed 
different histological tumour patterns, i.e. simple tubulopapillary (two cases) (Figure 4A-B-C) 
and complex (one case). No association was found between histological diagnosis and 
phenotype in the primary tumour (Pearson Chi-square, P=0.065; for statistics only the 
tubulopapillary and the solid carcinomas were considered because the other two types had 
only one case for phenotype). 
Six cases with tubulopapillary pattern displayed concordance between the primary tumour 
and its related lymph node metastasis whereas the other two cases showed discordance. In the 
solid pattern concordance was found in five cases and discordance in three. In the anaplastic 
and complex patterns both concordance and discordance were present with one case for each 
type. Comparing the four histological patterns, no differences in the percentages of 
concordance/discordance were evident (Pearson Chi square P=0.857, for statistics only the 
tubulopapillary and the solid carcinomas were considered because the other two types had 
only one case for each phenotype). 
Influence of the molecular phenotype and concordance/discordance on dog’s 
survival rate 
Table 1 reports the survival data of the 11 animals. Few data are available to group the 
subjects according to molecular phenotypes and concordance/discordance to perform survival 
analysis even though it appears that all five animals alive at 24 months post-surgery were 
concordant luminal A or luminal B cases. The other six dead animals bore primary 
tumour/lymph node concordant (2 basal-like and 2 c-erbB-2 overexpressing) or discordant (1 
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luminal A/normal like; 1 luminal B/normal-like) cases in which less differentiated molecular 
types were present in both sites or only in the lymph node compared to the live animals. 
Discussion 
Canine mammary carcinomas can become fatal due to the development of distant metastases. 
One of the most important prognostic factors in the diagnosis is the acknowledgment of 
metastases to the regional lymph node that represents an early step in metastatic spread [30]. 
Klopfleisch et al. [17] and Lu et al. [31] demonstrated that metastatic spread of canine 
mammary tumour to the lymph nodes is associated with a gene expression profile of increased 
cell cycle progression, altered cell differentiation and decreased growth factor signaling. 
Metastasis development is a complex process involving invasion, intravasation, survival in 
the bloodstream, extravasation and homing and proliferation at the site of metastasis [32]. 
Although some phenotypes showed greater aggressiveness and metastatic capability, only a 
selected subpopulation was able to metastatize in the multiple and heterogeneous tumour cell 
population. In this case the phenotype may have been transient and these selected cells have 
had an intrinsic program to transition to a phenotype enhancing their ability for heterotypic 
interaction and survival proliferation in distant organs [32] as Darwinian clonal evolution. 
Conversely, the metastatic process has also been described as a stochastic event, the primary 
tumour cells having equal metastatic capability, characterized by a phenotypic overlap 
between the primary tumour and its metastases [33,34]. Thus the identification of molecular 
phenotypes in primary tumour and metastases can provide predictive information on the most 
likely metastatic profile, not the condition in the primary tumour. 
Sassi et al. [9] identified three phenotypes out of the four detected by Gama et al. [8], 
demonstrating that basal-like subtypes were associated with a better outcome than luminal A 
and luminal B tumour, in contrast with the findings of Gama et al. [8]. The prognostic role of 
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c-erbB-2 overexpression remains controversial despite what is known in human medicine. 
According to a study by Hsu et al. [35], the relationship between the clinical course and 
protein expression of c-erbB-2 in dogs with malignant mammary neoplasia indicated a 
greater survival rate in tumour overexpressing c-erbB-2 compared to those having 
nonoverexpressed levels of antigen. Certainly, c-erbB-2 plays an important role in 
carcinogenesis, but does not seem to be directly correlated with progression to malignancy 
[35]. In the present investigation it seems that luminal A or B concordance should be 
considered a positive prognostic factor, whereas concordance for the other molecular types or 
discordance should not, even if these results await confirmation in a larger number of cases 
and proper statistical analysis. 
This study revealed four out of the five protein expression phenotypes of breast cancer in 
primary tumour (20 cases): luminal A (40%), luminal B (35%), c-erbB-2 overexpressing 
(10%) and basal-like (15%). The prevalence of luminal phenotypes (75%) over the others 
(25%) is in accordance with findings both in human [11,36,37] and veterinary [8;9] 
medicine. 
Based on the present study and in agreement with Brunetti et al. [38], labeling for CK and 
p63 would only appear necessary when a tumour is negative for ER, PR and c-erbB-2. 
With regard to luminal A and B phenotypes, the expression profiles of ER and PR are 
essential to decide on the application of endocrine therapy [39] in breast cancer and canine 
mammary neoplasia, and also seem to play a minor role in predicting tumour biological 
behaviour [40,41]. Wu et al.’s study [15] in breast cancer confirmed the observation that ER 
and/or PR could be lost when carcinomas metastasizes, thereby resisting endocrine therapy. 
The present study shows almost overlapping results, losing hormone receptors by moving 
from luminal A to basal-like (2 cases) and/or to normal-like (1 case) phenotypes and from 
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luminal B to c-erbB-2 overexpressing (2 case) and/or to basal-like (1 case), and/or to normal 
like (1case), confirming that the gene expression profile in canine mammary tumour may 
prove a helpful tool in clinical practice. Chang et al. [42] indicated that the ER or PR 
expression in dogs was associated with tumour size, clinical stage, and lymph node metastasis 
or distant metastases. Dogs with malignant mammary neoplasia and expression of both ER 
and PR had a longer survival rate than dogs with malignant mammary tumour that were ER 
positive but PR negative. This latest information on PR suggested that the receptor was a 
better outcome predictor than ER status alone and that its positive or negative expression 
could serve as a prognostic factor, especially in dogs with malignant neoplasia with ER 
expressed [42]. The present results disclosed a high prevalence of hormone receptor 
expression in the primary tumour, whose positivity was ensured by reactivity to least one of 
the two markers (ER and/or PR) (Table 3). The latest results indicate that there are grounds 
for the use of anti-hormone therapy in dogs, administering molecules other than those 
hitherto used in veterinary medicine (tamoxifen) as their side-effects are already well-known 
[24]. A similar analysis in lymph node showed a net loss of hormone receptor expression, 
namely ER. ER loss is a known adverse prognostic factor [42], and therefore its lack of 
expression in metastases is indicative. In this study, only five out of the 20 cases showed 
positivity to both ER and PR in the primary tumour, with persistent positivity in the lymph 
node metastasis in only two cases. The remaining three cases showed loss of one or both 
hormone receptor staining in the lymph node metastasis: loss of ER (case n°1), loss of PR 
(case n° 14) and concomitant loss of ER and PR (case n° 9). According to the literature, these 
cases should have a poor prognosis, justified by our phenotypes, but with maintained 
luminality in the first two cases, and a shift to c-erbB-2 overexpression in the third meaning a 
even worse evolution by the complete loss of ER and PR. 
Interestingly, cases n°3 and n°13 (Table 3) in which in lymph node metastasis occurred, lost 
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all the markers expressed in the primary tumour, likely due to the selection of a significantly 
aggressive cell subpopulation. The normal-like or multiple markers negative (MMN) subtype 
tumour have been shown to be negative for basal markers, such as CK5/6 and CK14 in our 
cases, and negative for other molecular markers. The majority of normal-like subtype tumour 
express CK8/18, CK19 (used in this study), with an absence of CK5/6 suggesting that these 
cells were most probably derived from a luminal gland cell [43]. The normal-like subtype is 
also included in the triple negative breast cancer group (TNBC) characterized by an 
aggressive clinical course, poor survival rate and, unlike the overexpressing hormone 
receptors or c-erbB-2-overexpressing tumour, is not amenable to hormone therapy or c-erbB- 
2-directed agents [44]. Although no correlation has been found between histological type and 
phenotype, the normal-like cases represent an exception. 
The present study identified five phenotypes in the lymph node metastases: luminal A (25%), 
luminal B (15%), c-erbB-2 overexpressing (20%), basal-like (30%) and normal-like (10%). 
The novel aspect of this study is the evaluation of the lymph node metastasis phenotypes and 
their correlation with the primary tumour, never hitherto applied to canine species. The 
relationship between the primary tumour and metastatic phenotype is defined by a 
concordance in 65% of cases and a discordance in the remaining 35%, suggesting the two 
main metastatic capability theories coexist. All seven discordant cases showed a progressive 
behavior, according to the prognostic value of molecular phenotypes reported by Gama et al. 
[8], suggesting phenotypic evolution with a worse prognosis from the primary tumour to 
lymph node metastasis. 
Conclusions 
Molecular phenotype classification is a new model urgently needed in veterinary medicine. 
This model will fill current gaps regarding prognosis and a targeted therapeutic approach, 
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since the primary tumour phenotype does not always overlap with that of its metastasis. 
According to the present findings, the primary tumour phenotype assumes a predictive 
therapeutic role only in concordant cases, meaning that there should be a concomitant 
evaluation of both the primary tumour and its lymph node metastasis. Treatment planning 
based only on the primary tumour phenotype can lead to therapeutic failures if the lymph 
node metastatic phenotype differs from that of the primary tumour. 
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2. MOLECULAR PHENOTYPE IN MAMMARY TUMOURS 
OF QUEENS: CORRELATION BETWEEN PRIMARY TUMOUR 
AND LYMPH NODE METASTASIS 
 
Introduction 
The heterogeneity of breast cancer is proverbial and raises the need for a revision of the WHO 
classification, which is purely morphological (Eusebi, 2010). Sorlie et al. (2001) laid the 
foundations for a new taxonomy demonstrating that changes in patterns of gene expression, 
analyzed by cDNA microarray techniques and hierarchical clustering, allow a "molecular 
portrait" to be defined for each tumour. The final goal of this system is to classify the breast 
cancers into subtypes, Luminal-A, Luminal-B, c-erbB-2 over-expressing, basal-like and 
Normal-like, based on the differences between these patterns (Sorlie et al., 2001). The 
existence of four different subtypes of breast cancer was confirmed by protein expression 
patterns assessed by IHC on tissue microarray (TMA), an efficient and reliable platform for 
sub-classifying breast cancers into relevant subtypes, using a limited number of markers 
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(Matos et al., 2005). So far, this molecular classification has been applied in veterinary 
medicine only in canine (mammary). 
The usefulness of molecular subtypes is their predictive capability for prognosis and targeted 
therapy (Peppercorn et al., 2008). The formulation of a molecular-based taxonomy and its 
application to feline clinical practice is necessary for a multimodal therapeutic approach and 
to increase the survival rate. 
Aim of the present study was: 1) to define the molecular phenotype of feline mammary 
carcinomas and their lymph node metastases according to a modified algorithm  by Sassi et 
al. (2010); 2) to demonstrate the concordance or discordance of the molecular profile between 
the primary tumour and lymph node metastasis. 
Materials and Methods 
Samples 
Specimens of mammary carcinomas from 21 female cats were collected from the data base of 
the Pathology Service of the Department of Veterinary Medical Science of Bologna 
University and from the Department of Animal Pathology of Pisa University. Each case 
consisted in primary mammary tumour and its related lymph node metastasis. No cases 
displayed systemic metastases.   Samples were available as haematoxylin and eosin stained 
sections, obtained from formalin-fixed and paraffin wax-embedded tissue block.   
Histological diagnosis and immunohistochemistry 
Histological diagnosis was achieved according to the WHO classification system (Misdorp et 
al., 1999). Seven consecutive 4 μm thick sections were cut from the paraffin wax blocks 
containing representative tumour samples and labelled by immunohistochemistry with the 
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following antibodies: anti-ER, -PR, -c-erbB-2, -CK5/6, -CK14, -CK19 and -p63. Data on the 
primary antibodies are summarized in Table 1. 
Table 1: Primary antibodies, resources and dilutions used in immunohistochemistry 
ANTIBODY 
(-ANTI) 
CLONE  MANUFACTURER DILUITION 
ER 6F11 
Novocastra Lab Ltd., Newcastle upon 
Tyne, UK 
1: 40 
PR PR88 Biogenex, San Ramon, CA, USA 1: 40 
c-erbB-2 Policlonal Dako, Glostrup, Denmark 1: 250 
Cytokeratins 5/6 D5/16B4 Zymed (South San Francisco, Ca) 1: 100 
Cytokeratin 14 
Ab-1 
(LL002) 
NeoMarkers (Fremont, Ca) 1: 300 
Cytokeratin 19 BA17 Dako (Glostrup, Denmark) 1: 50 
p63 4A4 Dako (Glostrup, Denmark) 1: 50 
 
Sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was blocked by 
immersion in 0.3% hydrogen peroxide for 20 min. Sections were then rinsed in Tris Buffer 
and antigen was retrieved with citrate buffer (2.1 g citric acid monohydrate/litre distilled 
water), pH 6.0 (except for CK 5/6 which use EDTA, pH 8.0), and heating for two 5-min 
periods in a microwave oven at 750 W, followed by cooling at room temperature for 20 min. 
All antibodies were incubated with the tissue sections overnight at 4°C, and their binding was 
revealed by a commercial streptavidin-biotin-peroxidase technique (LSAB Kit, Dako, 
Amsterdam, The Netherlands). Diaminobenzidine (0.05% for 10 min at room temperature) 
was used as chromogen. Slides were counterstained with Papanicolaou's haematoxylin.  
As negative control, the primary antibody was replaced with an irrelevant, isotype-matched 
antibody to control for non-specific binding of the secondary antibody. As positive controls to 
assess the cross-reactivity with feline tissues and the specificity of the immunohistochemical 
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stain, sections of normal feline uterus (for anti-ER and -PR antibodies) and feline skin (for 
anti-CK5/6, CK14, -CK19 and -p63 antibodies) were used following the same protocols. A 
human poorly differentiated invasive ductal mammary carcinoma (kindly provided by P. 
Viacava, Department of Oncology, University of Pisa, Italy) known to react with c-erbB-2 
antibody was used as positive control.  
The staining result was classified semi-quantitatively with a dichotomous evaluation: positive 
or negative. The sample was considered positive when presenting:  
• cytoplasmic stain in more than 1% of the invasive tumour cells for anti-CK-5/6 and 
anti-CK14 antibodies (Kim et al., 2006); 
• complete membranous stain in more than 10% of tumour cells for anti-c-erbB-2 
antibody (Millanta et al., 2005b);  
• nuclear stain in more than 5% of tumour cells for anti-ER and  anti-PR antibodies 
(Millanta et al., 2005a); 
• nuclear stain in more than 10% of tumour cells for anti-p63 antibody (Ramalho et al. 
2006).  
Molecular taxonomy 
The application of the panel grouped cases into five molecular subtypes according to an 
algorithm modified by Sassi et al. 2010 as follows: 
• Luminal-A: ER+ and/or PR+, c-erbB-2-, regardless of CK5/6, CK14, p63 staining.  
• Luminal-B: ER+ and/or PR+, c-erbB-2+, regardless of CK5/6, CK14, p63 staining. 
• c-erbB-2-overexpressing: ER-, PR-, c-erbB-2+ regardless of CK5/6, CK14, p63 
staining. 
• Basal-like: ER-, PR-, c-erbB-2- , CK5/6+ and/or CK14+ and/or p63 staining. 
• Normal-like: negative to all markers.  
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Results 
Diagnosis 
Six of the 21 primary tumours were classified histologically as solid carcinomas and 15 as 
simple tubulo-papillary carcinomas.  
Immunohistochemistry  
The immunohistochemistry for ER, PR, c-erbB-2, CK5/6, CK14, p63 in the primary tumour 
and respective lymph node metastasis is summarized in Table 2. In each case the epithelial 
origin of cancer was confirmed by CK19 staining. Hormonal receptor positivity (reactivity to 
ER and/or PR) was found in 11 out of 21 cases in the primary tumour, two ER and nine PR 
positive respectively (Table 2). The typical nuclear staining of ER and PR decreased 
substantially in the lymph node metastasis compared with the primary tumour (reactivity in 
only two out of 21 cases). C-erbB-2 over-expression was frequently observed both in the 
primary tumour (19 positive cases) and in the lymph node metastases (18 positive cases). 
As reported in Table 2, CK5/6 expression was less frequent than CK14 expression both in 
primary tumours (11/21 and 19/21, respectively) and in their lymph node metastases (9/21 
and 14/21, respectively). P63 was poorly expressed in primary tumours (four out of 21 
samples) and especially in metastases (one out of 21). 
Molecular phenotypes  
Based on the algorithm applied, molecular phenotypes were obtained in the primary 
mammary tumour and in their lymph nodes metastases (Table 3). Only three phenotypes 
(Luminal B (Fig. 1), c-erbB-2  over-expressing (Fig. 2), Basal (Fig. 3)) were diagnosed both 
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in primary tumours (11 (52.4%), eight (38.1%) and two (9.5%), respectively) and in lymph 
node metastases (two (9.5%), 16 (76.2%) and three (14.3%), respectively). 
Table 2: Summary of immunohistochemical staining 
SAMPLES 
ID 
PRIMARY MAMMARY TUMOUR LYMPH NODE METASTASIS 
ER PR c-erbB-2 CK 14 CK 5/6 p63 ER PR c-erbB-2 CK 14 CK 5/6 p63 
1 0 1 3 1 1 0 0 1 3 1 1 0 
2 0 0 2 1 0 0 0 0 2 1 0 0 
3 1 0 2 1 0 1 0 0 2 1 0 0 
4 0 1 1 1 0 0 0 0 1 0 0 0 
5 0 1 2 1 0 0 0 0 2 1 0 0 
6 1 0 3 1 1 0 0 0 2 0 0 0 
7 0 0 0 1 0 0 0 0 0 1 0 0 
8 0 0 1 1 1 0 0 0 1 0 0 0 
9 0 0 2 1 1 0 0 0 2 1 1 0 
10 0 0 2 1 1 1 0 0 1 1 0 0 
11 0 0 3 1 0 0 0 0 3 1 1 0 
12 0 1 1 1 1 0 0 0 0 1 1 0 
13 0 0 3 1 1 0 0 0 3 1 1 0 
14 0 1 3 1 0 0 0 0 3 0 0 0 
15 0 1 3 1 1 1 0 0 3 1 1 0 
16 0 0 2 1 0 0 0 0 2 1 0 0 
17 0 1 2 0 1 0 0 0 2 0 1 0 
18 0 1 2 1 1 1 0 0 2 1 1 1 
19 0 0 2 0 0 0 0 0 2 0 0 0 
20 0 1 2 1 1 0 0 1 1 1 1 0 
21 0 0 0 1 0 0 0 0 0 1 0 0 
0= 0%; 1= <25%; 2 <50%; 3 >50%  
 78 
 
 
Comparison between histological diagnosis and phenotype in primary mammary 
tumour  
The tubulopapillary pattern displayed three different phenotypes, i.e. Luminal B (seven 
cases), c-erbB-2 over-expressing (six cases) and Basal-like (two cases). The solid pattern was 
found in two phenotypes, namely Luminal B (five cases) and c-erbB-2 over-expressing (one 
case). No association was found between histological diagnosis and phenotype in primary 
tumour (Yates corrected Chi-square, P=0.46).  
Relationship between molecular phenotype in the primary mammary tumour and 
its related lymph node metastasis 
Phenotypic concordance was found in 12 of the 21 cases (57.14%) (eight c-erbB-2 over-
expressing, two Basal and two Luminal B). The phenotypic profile of primary tumours 
showed discordance from regional lymph node metastases in nine cases (42.86%) (eight 
Luminal B became c-erbB-2 over-expressing and one Luminal B became Basal-like in the 
lymph node metastasis) (Table 3).  
Relationship between histological diagnosis and concordance/discordance  
The same molecular phenotype (concordance) was found in the primary tumour and its lymph 
node metastasis in ten tubulo-papillary carcinomas, whereas a difference (discordance) 
between the two sites was found in the other five. As for the solid pattern concordance was 
found in two cases and discordance in four. No difference in the percentage of concordant and 
discordant cases emerged comparing the two histological patterns mentioned above (Yates 
corrected Chi-square, P=0.36). 
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Discussion  
To the best of our knowledge, no literature reports have addressed the immunophenotyping of 
feline mammary carcinomas. Only single markers such as c-erbB-2 over-expression and 
steroid receptors have been used to date (Millanta et al., 2005b; Rasotto et al., 2011). The 
present study analysed markers (ER, PR, c-erbB-2, CK5/6, CK14, p63) both singly and 
combined in the molecular phenotypes to detect possible changes from the primary tumour to 
its regional lymph node metastasis. Immunophenotyping is essentially based on the 
presence/absence of hormonal receptors (Fig. 1) and c-erbB-2 (Fig. 2), and basal markers 
(CK5/6, CK14 and p63) are the key for the phenotypic definition of negative hormone 
receptors (basal (Fig. 3) and normal-like) and c-erbB-2 tumours. Based on the present study, 
only if ER, PR and c-erbB-2 are negative is CK necessary (Fig. 3), otherwise it is useless and 
expensive. Gama et al. demonstrated in dogs that basal subtypes rarely express just one basal 
marker, but they frequently express several concomitant markers (Gama et al., 2008).   The 
present study exhibits some overlap with Gama’s results regarding basal phenotypes, and 
suggests a more undifferentiated profile. Lymph node metastases did not show any 
immunostaining to the primary tumour markers. No protein absent in the tumour was 
expressed in its metastasis. 
Given the well-known malignancy of feline mammary carcinomas (Misdorp, 1999) and the 
high frequency of c-erbB-2 over-expression, particularly in metastases, in the present study, it 
can be assumed that the c-erbB-2 over-expressing phenotype (Fig. 2) also leads to a worse 
prognosis in the cat as in human breast cancer (Sorlie et al., 2001). Planning an anti-c-erbB-2 
targeted therapy in queens bearing mammary carcinoma would therefore have a specific 
therapeutic value to counteract metastases.  
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In human medicine Toft et al. (2011) described the Basal-like phenotype as a distinctive 
molecular subtype with a basal epithelial gene signature and an aggressive clinical course 
characterized by early relapses and poor survival. They also found a prevalence of Basal-like 
breast cancer ranging from 12.3 to 36.7 of breast cancer cases (Toft et al., 2011). This range is 
similar to the percentage frequency found in this study on mammary tumours in queens, but 
the absence of outcome precludes any comment on the similarity between human and feline 
Basal-like phenotypes.  
The analysis of hormone receptors status disclosed a low expression of these markers both in 
the primary tumours and more markedly in their metastases. Indeed, normal mammary tissue 
and benign mammary tumours are mostly positive for ER and PR with respect to carcinomas, 
which are more often ER negative or positive in only few cases (Misdorp, 2002). High 
negative rates of ER seem to be a characteristic feature of feline mammary carcinomas 
compared with human and canine tumours, suggesting a lack of oestrogen dependence 
(Millanta et al., 2005a). The high number of ER/PR negative cases in cat mammary 
carcinomas reduces the frequency of the tumour classified as Luminal type by the applied 
tumour classification system: in this study Luminal A carcinomas were lacking and the 
frequency of Luminal B (Fig. 1) lesions was lower than c-erbB-2 over-expressing tumours 
(Fig. 2). The results suggest an association between a down-regulation of p63 expression and 
progression of the tumour mirroring breast ductal carcinoma (Wang et al., 2002; Lindsay et 
al., 2011). C-erbB-2 (Fig. 2) in this study was always over-expressed with a high frequency in 
the primary site as well as in the metastases associated with ER/PR expression (Luminal B) or 
not (c-erbB-2 over-expressing). Therefore anti-hormonal therapy alone is not indicated in 
queens bearing mammary carcinomas, even in cases with ER/PR expression, but should be 
associated with a target anti-c-erbB-2 therapy.  
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It has been debated for decades how cancer cells acquire metastatic capability. It is unclear 
whether metastases are derived from a distinct tumour cell subpopulation with higher 
metastatic potential within the primary site, or whether they originate from a random fraction 
of tumour cells (Weigelt et al., 2003). Our comparison between the phenotypes of a primary 
tumour and its lymph node metastasis displayed concordance in 57.1% cases and discordance 
in 42.9%, with a progressive loss of marker immunoreactivity in the lymph node metastasis 
with respect to the primary tumour. Human and canine Luminal A tumours are associated 
with higher survival rates and Basal-like and c-erbB-2-overexpressing subtypes are related to 
lower survival rates and more aggressive clinical behavior (Matos et al., 2005; Gama et al., 
2008). Hence, the progressive phenotypic discordance found in this study may signify a worse 
prognosis with worsening of the phenotype passing from the primary tumour to the lymph 
node metastasis. Phenotypic instability could be due to a tumoural cell sub-population that 
acquires metastatic ability during carcinogenesis. Conversely, phenotypic concordance of the 
primary tumour and metastasis could result from an intrinsic and early metastatic capability of 
the dominant phenotype in the primary tumour. Weigelt et al. (2005) reported that the ability 
to metastasize to distant sites is an early and inherent genetic property of primary breast 
cancer, and that gene expression profiles of primary breast tumours were maintained in their 
distant metastases (Weigelt  et al. 2005).  
 An overall concordance has been proven in the immunostaining of the single markers 
between primary tumours and metastasis, especially for c-erbB-2 over-expressing lesions, 
indicating that the cat may develop the selection of an early clone with worsening prognostic 
features rather than a malignant tumour progression. The discordance between the single 
markers, also reported in human medicine (Aitken et al., 2010), led to therapeutic failure 
when the therapy was only based on the primary tumour phenotype. Histological type is not 
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associated with the molecular phenotype, since several phenotypes are related to each 
histological type.   
Conclusions 
From a molecular standpoint, the taxonomic approach represents a powerful tool for the 
biological analysis of mammary tumours. The heterogeneity of the tumour is well-known, 
therefore  taxonomy based on these molecular differences is the key tool to formulate an 
appropriate therapy. As for the difference between the primary tumour and the regional lymph 
node metastasis, the primary tumour phenotype was not strictly predictive of the metastic 
phenotype in a high percentage of cases (43%) in this study. Both tumour sites (primary 
tumours and regional lymph node metastases) should be evaluated for accurate identification 
of the tumour profile (or profiles) and appropriate therapy designed to target both primary 
tumours and metastases in case of varying phenotypes. 
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Figures 
 
Fig. 1: Case 3. Luminal B phenotype: a ER staining, b c-erbB-2 staining. To be classified as 
luminal B phenotype, a neoplasm requires positivity to ER and/or PR and to c-erbB-2, while 
the results of the other antibodies (CK5/6 +/- , CK14+/-, p63+/-) are irrelevant. 400x. 
 
Fig. 2: Case 8. C-erbB -2-overexpressing phenotype: a ER staining, b c-erbB-2 staining. For 
the diagnosis of the c-erbB-2 phenotype, besides positivity to c-erbB-2 antibody, negativity to 
ER and PR is necessary, whereas the outcomes of the other antibodies (CK5/6 +/- , CK14+/-, 
p63+/-) are irrelevant. 400x 
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Fig. 3: Case 21. Basal-like phenotypes: a PR staining, b c-erbB-2 staining, c CK14 staining. 
Negativity to c-erbB-2, ER and PR and positivity to either CK (CK14 in the photo) or p63 is 
indicative of a basal phenotype. 400x 
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3. MOLECULAR PHENOTYPE OF PRIMARY MAMMARY 
TUMOURS AND DISTANT METASTASES IN FEMALE 
DOGS AND CATS 
 
Introduction 
In terms of prognosis and treatment approach, it is already well explained in the general 
section that the different phenotypes are associated with different clinical outcomes (Carey, 
2011; Sorlie et al., 2003). 
In the light of published findings, the metastatic process, i.e. the tumour’s ability to spread 
from its primary location to distant parts of the body
 
(Banfalvi, 2012), has become one of the 
most urgent, important and difficult issues to approach in human (Tarin, 2008) and animal 
cancer medicine. Among the possible sites of metastases, human (Tavassoli and Devilee, 
2003), canine (Klopfleisch
 
et al., 2010) and feline (Ginn et al., 2007) mammary tumours are 
known to spread to the regional lymph nodes, lungs, pleura, liver, adrenal glands, brain, 
kidneys and bone (Fountzilas et al., 2012; Kennecke et al., 2010). In human medicine, 
investigations conducted to associate breast tumour molecular subtypes with the site of 
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metastatic disease have reported conflicting results (Arnedos et al., 2012; Fountzilas et al., 
2012; Kennecke et al., 2010). Some studies found a low risk of brain metastases with luminal 
A and B disease, but a high risk for pleural relapse
 
(Smid et al., 2008). Basal-like and normal-
like tumours had a distinctive pattern of relapse, with higher frequencies of lung, brain, liver, 
locoregional and distant lymph node metastasis (Arnedos et al., 2012; Fountzilas et al., 2012; 
Kennecke et al., 2010) compared to the frequency of c-erbB-2 overexpressing phenotype. 
Other studies showed that locoregional relapse (Lester, 2010), and distant metastases in brain 
(Blows et al., 2010), lung, liver and soft tissues (Aleskandarany et al.; 2012; Fountzilas et al., 
2012) were more common in c-erbB-2 overexpressing tumours compared to basal and 
normal-like phenotypes. Bone metastases also presented a higher frequency with luminal B 
disease (Fountzilas et al., 2012; Kennecke et al., 2010). 
Few veterinary studies have considered the molecular phenotype of lymph node metastases in 
comparison with the primary mammary tumour phenotype (Beha et al., 2012; Brunetti et al., 
2013). The phenotype of feline mammary carcinomas and their lymph node metastases was 
recently determined
 
(Brunetti et al., 2013), and the same comparison made for canine 
mammary tumours (Beha et al., 2012). No data are yet available on the molecular phenotypes 
of distant metastases and their correlation with the primary mammary tumour and its related 
lymph node metastasis.  
Therefore, the present study aimed to evaluate the molecular trend of cancer from its primary 
location to metastatic sites in three cats and two dogs with mammary tumours. 
Materials and Methods 
Samples 
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Tissue samples of mammary carcinomas from two female dogs and three female cats were 
collected from the database of the Pathology Service of the Department of Veterinary Medical 
Science, University of Bologna, and from the Department of Veterinary Sciences, University 
of Pisa. All the animals underwent autopsy. 
Cases were selected based on both the primary mammary neoplasm and histological grade III 
(grade III: invasive carcinoma with distant metastases) according to a previous study 
(Gilbertson et al., 1983). Samples were available as sections stained with hematoxylin and 
eosin and obtained from formalin-fixed and paraffin-embedded tissue blocks. 
Histological diagnosis and immunohistochemistry 
Histological diagnosis was made according to the WHO classification system
 
(Misdorp et al., 
1999). Six consecutive 4-μm thick sections were cut from the paraffin blocks containing 
representative tumour samples and three of them were labeled by immunohistochemistry with 
the following antibodies: anti-ER, -PR, -c-erbB-2. According to a previous study (Brunetti et 
al., 2013), samples presenting negative staining to the above antibodies were labeled by 
immunohistochemistry with anti-CK5/6, -CK14, and -p63 antibodies. Data on the primary 
antibodies are summarized in Table 1. 
Sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was blocked by 
immersion in H
2
O
2
 0.3% in methanol for 20 min. Sections were then rinsed in Tris buffer and 
antigen was retrieved with citrate buffer (2.1 g citric acid monohydrate/liter distilled water), 
pH 6.0 (except for CK5/6 which used EDTA, pH 8.0), and heated for two 5-min periods in a 
microwave oven at 750 W, followed by cooling at room temperature for 20 minutes. 
All antibodies were incubated with the tissue sections overnight at 4°C, and their binding was 
revealed by a commercial streptavidin-biotin-peroxidase technique (LSAB Kit, Dako, 
Amsterdam, The Netherlands). Diaminobenzidine (0.05% for 10 minutes at room 
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temperature) was used as chromogen. Slides were counterstained with Papanicolaou's 
hematoxylin. As a negative control, the primary antibody was replaced with an irrelevant, 
isotype-matched antibody to control for non-specific binding of the secondary antibody. As 
positive controls to assess the cross-reactivity with canine and feline tissues and the 
specificity of the immunohistochemical stain, sections of normal canine and feline uterus (for 
anti-ER and –PR antibodies), canine and feline skin (for anti-CK5/6, -CK14, and -p63 
antibodies) were used following the same protocols. A human poorly differentiated invasive 
ductal mammary carcinoma (kindly provided by P. Viacava, Department of Oncology, 
University of Pisa, Italy) known to react with c-erbB-2 antibody was used as positive control. 
Table 1: Immunohistochemical panel of antibodies  
ANTIBODY        
 (-ANTI) 
CLONE MANUFACTURER DILUTION 
ER (dog) B-10 Abcam, Cambridge, UK 1: 300 
ER (cat) 
6F11 
Novocastra Laboratories Ltd., Newcastle 
upon Tyne, UK 
1:40 
PR (dog) PR4-12 Oncogene TM, Boston, MA, USA 1: 100 
PR (cat) PR88 Biogenex, San Ramon, CA, USA 1:40 
c-erbB2 Polyclonal Dako, Glostrup, Denmark 1: 250 
Cytokeratins 5/6 D5/16B4 Zymed (South San Francisco, CA, USA) 1: 100 
Cytokeratin 14 Ab-1 (LL002) NeoMarkers (Fremont, CA, USA) 1: 300 
Cytokeratin 19 BA17 Dako (Glostrup, Denmark) 1: 50 
p63 4A4 Dako (Glostrup, Denmark) 1: 50 
 
The staining result was classified semi-quantitatively with a dichotomous evaluation: positive 
or negative. The sample was considered positive when presenting: 
• cytoplasmic stain in more than 1% of the invasive tumour cells for anti- CK5/6 and anti-
CK14 antibodies (Kim et al., 2006); 
• complete membranous stain in more than 10% of tumour cells for anti- c-erbB-2 antibody 
according to the Hercept-test (Millanta et al., 2005b); 
 93 
 
 
• nuclear stain in more than 5% of tumour cells for anti-ER and anti-PR antibodies (Millanta 
et al., 2005a); 
• nuclear stain in more than 10% of tumour cells for anti-p63 antibody (Ramalho et al., 2006). 
Molecular taxonomy 
The application of the panel allowed cases to be grouped into five molecular subtypes 
according to a modified algorithm (Sassi et al., 2010) as follows: 
• Luminal-A: ER+ and/or PR+, c-erbB-2–, regardless of CK5/6, CK14, p63 staining. 
• Luminal-B: ER+ and/or PR+, c-erbB-2+, regardless of CK5/6, CK14, p63 staining. 
• c-erbB-2 overexpressing: ER–, PR–, c-erbB-2+ regardless of CK5/6, CK14, p63 staining. 
• Basal-like: ER–, PR–, c-erbB-2–, CK5/6+ and/or CK14+ and/or p63+. 
• Normal-like: negative to all markers 
Results 
Diagnosis 
All individual data are listed in Table 2. The first three cases were all from European shorthair 
feline samples classified as tubulopapillary carcinomas with different metastatic sites. In the 
first case metastases were present in locoregional lymph node and lung (Fig. 1). The second 
case developed metastases in locoregional lymph node, lung and muscle. The last feline case 
presented metastases in locoregional lymph node, lung and spleen. Canine samples were 
collected from a German Shepherd and a Hungarian Hound. The two canine mammary 
tumours were histologically diagnosed as anaplastic and tubulopapillary carcinoma 
respectively with metastases in locoregional, deep, lombo-aortic lymph node, lung, ovary and 
adrenal gland in the first case and in the lung and brain in the second carcinoma (Fig. 2). At 
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the time of the investigation no records were available for the involvement of the locoregional 
lymph node of the second carcinoma (Table 2).  
Table 2: Individual data and molecular phenotypes 
N° 1 2 3 4 5 
SPECIES Feline Feline Feline Canine Canine 
BREED European European European German Shepherd Hungarian Hound 
AGE (years) NA NA 19 10 11,8 
HISTOTYPE 
Tubulopapillary 
carcinoma 
Tubulopapillary 
carcinoma 
Tubulopapillary 
carcinoma 
Anaplastic 
carcinoma 
Tubulopapillary 
carcinoma 
MAMMARY TUMOUR 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
LOCOREGIONAL 
LYMPH NODE 
METASTASIS 
c-erbB-2 
overexpressing 
Basal-like 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
NA 
PULMONARY 
METASTASIS 
c-erbB-2 
overexpressing 
c-erbB-2 
overexpressing 
NP 
c-erbB-2 
overexpressing 
Basal-like 
BRAIN METASTASIS NP NP NP NP 
c-erbB-2 
overexpressing 
LOMBO-AORTIC 
LYMPH NODE 
METASTASIS 
NP NP NP 
c-erbB-2 
overexpressing 
NP 
DEEP INGUINAL 
LYMPH NODE 
METASTASIS 
NP NP NP 
c-erbB-2 
overexpressing 
NP 
KIDNEY METASTASIS NP NP NP NP NP 
SPLEEN METASTASIS NP NP 
c-erbB-2 
overexpressing 
NP NP 
MUSCLE METASTASIS NP 
c-erbB-2 
overexpressing 
NP NP NP 
OVARY METASTASIS NP NP NP 
c-erbB-2 
overexpressing 
NP 
ADRENAL GLAND 
METASTASIS 
NP NP NP 
c-erbB-2 
overexpressing 
NP 
NA= not available; NP= not present 
Immunohistochemistry 
None of the cases showed positivity to hormone receptors ER and PR. C-erbB-2 
overexpression was observed in the primary sites of all five cases, in locoregional lymph node 
metastasis (3 out of 4 cases: 2 cats and 1 dog) and in distant metastases (9 locations: 4 in cats 
and 5 in dogs). Considering the two cases (locoregional lymph node metastasis of case no.2 
and pulmonary metastasis of case no.5) with hormone receptors and c-erbB-2 negative 
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staining, the expression of antibody anti-CK5/6, CK14 and p63 was evaluated. The 
pulmonary metastasis of case no.5 stained only for CK14, with the other three antibodies not 
being expressed. The locoregional lymph node metastasis of case no. 2 showed positive 
staining for CK14 and negative staining for CK5/6 and p63. 
Molecular taxonomy 
Based on the modified algorithm (Sassi et al., 2010), only two out of the five different 
molecular phenotypes were obtained in the primary mammary tumours and their locoregional 
lymph node and distant metastases in the dogs and cats examined. In the feline cases, all the 
primary tumours, lymph node metastasis and distant metastases were diagnosed as c-erbB-2 
overexpressing phenotype (Fig. 1) with the exception of the locoregional lymph node 
metastasis in case no. 2 that was diagnosed as basal-like. The two canine cases were classified 
as c-erbB-2 overexpressing phenotype in the primary site, whereas the lymph node metastasis 
and distant metastases except the pulmonary metastasis of case no. 5 were diagnosed as basal-
like (Table 2) (Fig. 2). 
Relationship between molecular phenotype in the primary mammary tumour, its 
related lymph node and distant metastases 
Concordance (the same phenotypes in the primary mammary site and its related lymph node 
and distant metastases), was found in three out of the five cases (all c-erbB-2 overexpressing 
phenotypes) (Fig. 1). Two cases showed discordance with the locoregional lymph node (case 
no. 2, cat, Table 2) and pulmonary distant metastases (case no. 5, dog, Table 2) showing a 
different phenotypic profile from the primary tumour (c-erbB-2 overexpressing vs basal-like) 
(Fig. 2). 
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Discussion 
In human medicine, molecular phenotypes are determined in both the primary tumour site and 
in metastases to minimize any therapeutic margin of error if the primary phenotype differs 
from that of the metastatic lymph node and/or systemic metastases. In breast cancer
 
(Sorlie et 
al., 2003) and lately canine (Beha et al., 2012; Gama et al., 2008; Sassi et al., 2010) and 
feline
 
(Brunetti et al., 2013) mammary neoplasms, the molecular portrait-based classification 
system has been adopted as a valid tool to evaluate predictive-prognostic models and/or target 
therapies (Peppercorn et al., 2008). Many investigations have demonstrated that different 
molecular phenotypes resulted in different prognoses and target treatments. Overall- and 
relapse-free survival times were longer in luminal tumours compared to c-erbB-
2overexpressing, basal and normal-like phenotypes
 
(Gama et al., 2008; Sorlie et al., 2003). 
Metastasis to the regional lymph node is considered one of the most important prognostic 
factors, representing an early step in metastatic spread (Lester, 2010) and the development of 
distant metastases can be fatal in canine and feline mammary carcinomas (Klopfleisch
 
et al., 
2010; Morris et al., 2008). 
The molecular phenotypes of 21 primary feline mammary tumours were determined and 
compared to their related lymph node metastases obtaining three out of the five known 
phenotypes (luminal B, c-erbB-2 overexpressing, basal-like) both in the primary neoplasm 
and in the related lymph node metastasis with 57.1% concordant cases and 42.9% discordant 
cases
 
(Brunetti et al., 2013). The same comparison was studied in 20 bitches and the results 
disclosed four molecular phenotypes (luminal A, luminal B, c-erbB-2 overexpressing, basal-
like) in the primary tumour and all five phenotypes in the lymph node metastasis (luminal A, 
luminal B, c-erbB-2 overexpressing, basal-like and normal-like) with concordance in 65% of 
cases and discordance in the remaining 35% 
 
(Beha et al., 2012).  
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The results of the present study in feline and canine carcinomas differed from the above 
findings since all five primary mammary tumours displayed the same c-erbB-2 
overexpressing phenotype. The phenotype was maintained in all the lymph nodes and distant 
metastases except for one lymph node and one lung metastasis that were discordant with 
respect to the primary tumour. A possible explanation for the prevalence of the c-erbB-2 
overexpressing phenotype in primary tumours is likely to be the small number of cases 
reported in the present study, but it could also result from the higher malignancy of the c-
erbB-2 overexpressing phenotype than the luminal phenotypes, as already demonstrated in 
human medicine (Perou et al., 2000; Sorlie et al., 2003). In fact, a previous study 
demonstrated that ER and/or PR could be lost when the neoplasm metastasizes (Wu et al., 
2008). The present findings are in accordance with the results reported for cats (Brunetti et 
al., 2013; Millanta et al., 2005b) that had a high frequency of c-erbB-2 overexpression 
particularly in the lymph node metastases, and the well-known malignancy (Misdorp et al., 
1999) of feline mammary carcinomas. Therefore, it can be assumed that the c-erbB-2 
overexpressing phenotype is associated with an increased risk of metastases as in human 
breast cancer (Aleskandarany et al., 2012; Arnedos et al., 2012; Fountzilas et al., 2012; 
Steinman et al., 2007). Different studies on dog tumour phenotypes (Gama et al., 2008; 
Ressel et al., 2013) showed a higher survival rate and lower aggressiveness associated with c-
erbB-2 overexpressing phenotypes, which differed substantially from the results obtained in 
this investigation so that more cases are required before making any assumptions or 
comparisons. An overall concordance for c-erbB-2 overexpressing phenotypes between 
primary tumours and metastases was found in female dogs and cats. This result is in 
agreement with the cited study on feline tumours
 
(Brunetti et al., 2013), where a phenotypic 
concordance of c-erbB-2 overexpressing between primary feline mammary tumour and its 
related lymph node metastasis was found in 38% of cases with 16 out of 21 primary 
 98 
 
 
mammary tumours presenting the c-erbB-2 overexpressing phenotype in their related lymph 
node metastases. 
Phenotypic concordance of the primary tumour and its related lymph node and distant 
metastases could be explained by an intrinsic and early metastatic capability of the dominant 
phenotype in the primary tumours that is maintained in their distant metastases (Weigelt et al., 
2005).  
Planning an anti-c-erbB-2-targeted therapy in veterinary medicine, particularly in female cats 
bearing mammary carcinomas could therefore have a specific therapeutic value to counteract 
metastases. Given the affinity of phenotypes to metastasize in different sites, the present 
results are in agreement with in literature reports on breast cancer showing that the c-erbB-2 
overexpressing phenotype has an increased tendency to metastasize to distant (Aleskandarany 
et al., 2012; Fountzilas et al., 2012) and locoregional organs (Blows et al., 2010). 
Two cases in our study presented discordance when the primary site phenotype differed from 
that or those in the lymph node and/or distant metastases. Case no.2, a cat, presented c-erbB-2 
overexpression in both the primary mammary phenotype and distant pulmonary and muscle 
metastases, but this changed to the basal-like phenotype in the locoregional lymph node 
metastasis. These results coincide with those obtained in a human breast cancer study where 
locoregional relapse was associated with the triple negative phenotype (Fountzilas et al., 
2012). The second discordant case, no.5, was a dog presenting the c-erbB-2 overexpressing 
phenotype in the primary mammary tumour and the same phenotype in the brain metastasis 
that became basal-like in the lung metastasis. In human medicine, brain metastasis is more 
common in triple negative phenotypes (basal and/or normal-like phenotype) (Fountzilas et al., 
2012; Kennecke et al., 2010), and in the c-erbB-2 phenotype (Lester, 2010), in accordance 
with our case no.5. The basal-like pulmonary metastasis showed overlaps with some reports 
of breast cancer (Arnedos et al., 2012; Kennecke et al., 2010; Peng, 2012). However, these 
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similarities do not identify a standard behavior of the different phenotypes in various 
metastatic sites since human literature reported indications of cases but not a known behavior. 
The two discordant cases may be explained by the loss of one or more receptors or by the 
selection of a subpopulation with an intrinsic program of transition to a different phenotype 
enhancing their ability for heterotypic interaction and survival proliferation in distant organs 
(Aleskandarany et al., 2012) as Darwinian (Nakshatri et al., 2009) evolution.  
In canine and feline literature (Brunetti et al., 2013; Beha et al., 2012) a greater rate of 
discordance regarding the relationship between the phenotype of the primary tumour and 
lymph node metastasis is reported. Otherwise, in this study, among the primary tumour and 
distant metastases a prevalence of concordant cases is observed.   
Conclusions 
In conclusion, this study, although limited to five cases, confirmed the existence of both 
biological phenomena of concordance and discordance in metastatic sites. The prevalence of 
concordance between primary and metastatic sites supports the predictive therapeutic value of 
the primary tumour phenotype, minimizing any margin of error which can occur in rare 
discordant cases. 
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Figures 
 
Fig. 1: Cat: Concordance between primary mammary tumour and locoregional and distant 
metastases. C-erbB-2 overexpressing concordant case with PR– and c-erbB-2+ [A, D (400x. 
Bar, 38μm)] in the primary neoplasia, PR– and c-erbB-2+ [B, E(400x. Bar, 38μm)] in the 
lymph node metastasis and PR– and c-erbB-2+ [C, F (400x. Bar, 38μm)] in the pulmonary 
metastasis. 200x. Bar, 76μm 
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Fig. 2: Dog: Discordance between primary mammary tumour and distant metastases. 
Discordant case showing c-erbB-2 overexpressing phenotype ER–, c-erbB-2+, CK14– (A, D, 
G) in the primary tumour becoming basal-like ER–, c-erbB-2–, CK14+ [B, E, H(400x. Bar, 
38μm)] in the pulmonary metastasis and c-erbB-2 overexpressing phenotype ER–, c-erbB-2+, 
CK14– [C, F (400x. Bar, 38μm), I] in the brain metastasis. 200x. Bar, 76μm 
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4. MORPHOLOGY OF THE MYOEPITHELIAL CELL: 
IMMUNOHISTOCHEMICAL CHARACTERIZATION FROM RESTING 
TO MOTILE PHASE  
 
Introduction 
Mammary gland tumours of dogs are formed by both epithelial (epithelium and 
myoepithelium) and mesenchymal components. The origin of the mesenchymal cells is still 
debated. The elevated frequency of tumours showing myoepithelial or basal cell proliferation 
is a unique feature of canine mammary tumours [1]. In the normal mammary gland, the 
lumina are delimitated by an inner layer of polarized epithelial cells resting on two outer or 
basal layers of epithelial and myoepithelial cells [2]. Both basal and myoepithelial cells 
synthesize the basement membrane of ducts and alveoli and form a structural barrier between 
the luminal epithelial cells and the surrounding stroma [3]. In ducts, myoepithelial cells form 
a nearly continuous layer of cells oriented parallel to the long axis of the ducts. This layer 
surrounds the luminal epithelial cells and separates them from the basement membrane and 
the stroma. In alveoli, the myoepithelial cells are discontinuous, forming a basket-like 
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network around the alveoli, allowing some luminal epithelial cells to contact the basement 
membrane directly [3–5]. Therefore, the myoepithelium is not only located in an ideal 
position to communicate between these two compartments, but it is also positioned to provide 
important regulatory signals for the maintenance of normal cell structure [5]. Based on 
immunohistochemistry, the three layers of cells of the normal mammary gland display 
different markers: the luminal epithelium is labeled by CK19, and the basal cells and 
myoepithelial cells are stained by CK5/6 [6] and CK14 [2] and p63, Alpha-SMA, and VIM 
[2]. Myoepithelial cells are contractile elements exhibiting a combined epithelial and 
smoothmuscle immunoprofile. Themarkers mentioned above are expressed in the cytoplasm, 
except for p63 which is a nuclear marker [1]. The myoepithelial cell layer is the sole source of 
tumour suppressor p63, which is significantly inhibited on proliferation and invasion of 
associated tumour cells [7]. In addition, basal myoepithelial cells in the normal mammary 
gland are occasionally labeled by ER antibody [8], which is used for the molecular-based 
classification of canine mammary tumours [9, 10]. Distinct myoepithelial cell morphologies 
can be recognized in canine complex and mixed tumours: resting and proliferative suprabasal 
myoepithelial cells and spindle and stellate motile interstitial myoepithelial cells. Suprabasal 
cells are located between the basement membrane and the luminal epithelium and exhibit 
flattened spindle (resting cells) or polygonal morphologies (proliferative cells). Interstitial 
cells are frequently arranged in solid nests apposed to epithelial elements or isolated in the 
interstitium [1, 11]. Spindle and stellate myoepithelial cells differentiate toward a more 
general contractile phenotype [12]. Interstitial myoepithelial cells may eventually become 
fibroblast-like cells, showing only VIM immunoreactivity [11]. The myoepithelial 
differentiation may culminate in the formation of various mesenchymal tissues, including 
cartilage and bone in canine mammary mixed tumour. 
 110 
 
 
The acquisition of typical features of mesenchymal cells is likely to originate through 
epithelial-mesenchymal transition (EMT). EMT is a biological phenomenon that allows a 
polarized epithelial cell, which normally interacts with the basement membrane via its basal 
surface, to undergo multiple biochemical changes enabling it to assume the traits and 
functions of mesenchymal cells [13]. 
Aim 
This paper will focus on various aspects of myoepithelial cells and mammary tumours in 
dogs, specifically (1) characterization of the four different myoepithelial cell morphological 
types in the normal and neoplasticmammary gland using a panel of antibodies and (2) the 
immunohistochemical changes in myoepithelial cells from an epithelial to a mesenchymal 
phenotype. 
Materials and Methods 
Samples  
Mammary gland specimens of 29 female dogs were retrieved fromthe database of the 
Anatomopathological Service of the Faculty of Veterinary Medicine of Bologna. The subjects 
belonged to different breeds: mongrel (n = 13), German shepherd (n = 3), Poodle (n = 3), 
Yorkshire Terrier (n = 3), Dachshund (n = 2), Setter (n = 1), Pointer (n = 1), Cocker spaniel (n 
= 1), Schnauzer (n =1), and Siberian Husky (n = 1); they were all females, with an average 
age of 9.20 ± 2.28 years (mean ± SD). The tumours consisted of: 3 benign myoepithelial 
tumours, 3 malignant myoepithelial tumours, 7 carcinomas in benign mixed tumours, and 16 
complex carcinomas (the last two groups were differentiated by the presence of cartilage 
and/or bone in the mixed tumours). In addition, 29 specimens from normal mammary glands 
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of the same tumour line and 3 mammary samples from 3 healthy nonmammary tumour 
bearing female dogs were evaluated. Tumours were classified according to Misdorp et al. [14] 
and Goldschmidt et al. [15] into benign myoepithelial tumours: a rare neoplasm composed of 
myoepithelial cells arranged in short bundles admixed with an extracellular fibrillar 
basophilic material; malignant myoepithelial tumours: different from the benign variant with 
more polymorphic myoepithelial cells; complex carcinoma: a carcinoma composed of both 
luminal epithelial and myoepithelial components; carcinoma in benign tumour: a tumour with 
foci of malignant-appearing epithelial cells or distinct nodules of such cells occurring together 
with mesenchymal cells that have produced cartilage and/or bone possibly in combination 
with fibrous tissue. 
Immunohistochemistry  
Four μm thick sections were cutfrom formalin-fixed paraffin-embedded blocks containing 
representative tumour samples. Immunohistochemistry for the following markers was done on 
these tissues: CK19, ER, CK5/6, CK14, VIM, Alpha-SMA, p63. Sections were dewaxed in 
toluene and rehydrated. Endogenous peroxidase was blocked by immersion in 0.3% hydrogen 
peroxide for 20min. Sections were then rinsed in Tris buffer. Antigen retrieval was performed 
with citrate buffer (2.1 g citric acid monohydrate/liter distilled water), pH 6.0 (except for 
CK5/6 and ER, which used EDTA, pH 8.0), and heating for two 5 min periods in a 
microwave oven at 750 W, followed by cooling at room temperature for 20 min. The primary 
antibodies are summarized in Table 1. All primary antibodies were incubated overnight at 
4◦C, followed by a commercial streptavidin-biotin-peroxidase technique (LSAB Kit, Dako, 
Amsterdam, The Netherlands). Diaminobenzidine (0.05% for 10min at room temperature) 
was used as chromogen. Slides were counterstained with Papanicolaou’s hematoxylin. 
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As a negative control, the primary antibody was replaced with an irrelevant, isotype-matched 
antibody to control for nonspecific binding of the secondary antibody. Positive tissue 
controls using the same IHC protocols included canine normal mammary gland (anti-CK19, -
ER, -CK14, -VIM, Alpha-SMA, -p63 antibodies) and canine skin (anti-CK5/6). The number 
of positive cells by each marker was calculated semiquantitatively: − = no stained cells, ± = 
less than 5% positive cells, + = 5–50% positive cells, ++ = more than 50% positive cells. 
Cases were considered positive for ER when nuclear staining was observed in at least 5% 
tumour cells [16]. 
Table 1: Primary antibodies, resources and dilutions used in immunohistochemistry   
Antibody (anti-) Clone Manufacturer Dilution 
P63 4A4 Dako (Glostrup, Denmark) 1:50 
Αlpha-SMA 1A4 Dako (Glostrup, Denmark) 1:100 
Cytokeratin 19 BA17 Dako (Glostrup, Denmark) 1:50 
Cytokeratin 14 Ab-1 (LL002) NeoMarkers (Fremont, Ca) 1:300 
Cytokeratins 5/6 D5/16B4 Zymed (South San Francisco, Ca) 1:100 
VIM V9 Dako (Glostrup, Denmark) 1:100 
ER 1D5 Dako (Glostrup, Denmark) 1:25 
Results 
Four types of myoepithelial cells were recognized on the basis of their morphology. The 
resting subtype exhibitedvthe elongated features of spindle cells in close contact withvluminal 
epithelial cells as well as proliferating suprabasal cellsvthat instead showed a polygonal shape 
(Figure 1(a)). The interstitialmotile cells were observed both forming nests (the spindle type 
lined nests and the stellate cells constituted the nest core) and isolated in the interstitium 
(Figure 2(a)). 
Normal Mammary Gland 
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 In the 3 control cases, all resting and proliferative suprabasal myoepithelial cells were 
labeled by p63, CK14, Alpha-SMA, and VIM. Resting and proliferative suprabasal 
myoepithelial cells did not express CK19 in any of the cases. 
Table 2: Immunohistochemical results for suprabasal and motile myoepithelial cells 
 
Mammary Tissue from the Same Line of the Mammary Tumour. 
In the 29 normal tissues in the same line as the tumours, all resting and proliferative 
suprabasal myoepithelial cells were labeled by p63, CK14, Alpha-SMA, and VIM. CK5/6 
was positive in all but four cases and ER was detected in 12 cases. CK19 expression was only 
observed in the luminal epithelium. Myoepithelial motile interstitial cells were not observed. 
All the results are summarized in Table 2. 
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Mammary Tumours  
Immunohistochemical results for suprabasal (Figure 1) and motile cells (Figure 2) using p63, 
CK14, CK5/6, CK19, Alpha-SMA, VIM, and ER are summarized in Table 2. CK5/6 labeled: 
suprabasal resting cells in 16 of the 29 cases (5 carcinomas in benign mixed tumours and 11 
complex carcinomas). CK 5/6 also labeled proliferativesuprabasal and spindle motile cells in 
10 cases (3 carcinomas in benign mixed tumours and 7 complex carcinomas). Stellate motile 
cells were present in 25 cases (1 benign myoepithelial tumour, 3 malignant myoepithelial 
tumours, 5 carcinomas in benign mixed tumours and 15 complex carcinomas) but were 
negative for CK5/6. Cartilage in mammary mixed tumours was always negative. CK14 
showed positivity in 23 cases in resting cells (with the exception of 1 complex carcinoma and 
benign and malignant myoepithelial tumours), in 22 cases in proliferative cells (6 carcinomas 
in benign mixed tumours and 15 complex carcinomas) with a trend to lose the expression 
when these cells had acquired the more motile phenotype of spindle cells (positive in 2 benign 
and 3 malignant myoepithelial tumours, 2 carcinomas in benign mixed tumours and 2 
complex carcinomas). Chondrocytes of mixed tumours were negative. VIM was positive in 
suprabasal cells in the 23 cases of carcinoma in benign tumour and complex carcinoma and in 
motile myoepithelial cells in all 29 cases. Stromal cells were positive in all cases. Cartilage 
was VIM positive in all 7 carcinomas in benign-mixed tumours. Alpha-SMA labeled resting 
and proliferative suprabasal myoepithelial cells in 23 carcinomas in benign-mixed tumours 
and complex carcinomas. The spindle cells in 10 cases (5 carcinomas in benign mixed tumour 
and 5 complex carcinomas) showed positivity for Alpha-SMA. In each case, except for 
two complex carcinomas, stellate cells were negative. Stroma showed positivity in only 6 
cases (1 carcinoma in benignmixed tumour and 5 complex carcinomas). P63 was detected in 
resting and proliferative suprabasal myoepithelial cells of the 23 cases of carcinoma in benign 
 115 
 
 
mixed tumour and complex carcinoma. All spindle and stellate motile cells were negative. 
Stromal cells and cartilage were negative. ER expression was present in 11 
suprabasalmyoepithelial cells (4 carcinomas in benign-mixed tumours and 7 complex 
carcinomas); spindle and stellate motile cells were positive in 9 cases (3 carcinomas in 
benign-mixed tumours and 6 complex carcinomas). Cartilage of mixed tumours was negative. 
Resting and proliferative suprabasal and spindle/stellate motile myoepithelial cells did not 
express CK19 in any of the tumours examined. Cartilage of mixed tumours was also negative 
for CK19. 
Discussion 
Based on the findings of Gama et al. [1] and Tateyama et al. [11], four morphological types 
of myoepithelial cells are present in the mammary gland: resting and proliferative suprabasal 
myoepithelial cells lining alveoli and ducts and spindle and stellate interstitial motile cells, 
which lie in the interstitial space where they may be arranged in nests. Myoepithelial markers, 
such as p63, CK5/6, CK14, Alpha- SMA, and VIM, proved to be valuable diagnostic adjuncts 
to facilitate the evaluation of complex and mixed proliferations. CK19 is considered the gold 
standard marker for luminal epithelium and was used to avoid any misdiagnosis with 
myoepithelial cells. Because of cross-reactivity patterns and the fact that lesional foci are 
typically minute, none of the myoepithelial markers enjoyed 100% sensitivity and specificity 
for myoepithelial cells. As such, at least 2 markers should be used to evaluate any given focus 
[17]. Based on our results, the best marker for suprabasal cells was p63 especially in 
association with CK14, which was limited to mature (basal) myoepithelial cells and, to 
a lesser extent followed by CK5/6, Alpha-SMA and VIM (Figure 1). However, CK5/6 also 
marked luminal epithelial cellsmaking it difficult to distinguish them fromproliferative 
suprabasal myoepithelial cells [2]. Morphologically, both epithelial and myoepithelial cells 
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may have a polygonal shape. A characteristic of both CK14 and CK5/6, but not of p63, alpha-
SMA, and VIM, was their reduced expression in myoepithelial cells in the suprabasal 
proliferative state. CK14, CK5/6, and p63 expression was gradually lost in cells in the spindle 
and stellate motile state. Alpha-SMA and VIM were present in spindle motile myoepithelial 
cells with different degrees of intensity. Only VIM proved to be a consistent marker for 
stellate motile myoepithelial cells. In this study, the stellate motile myoepithelium was 
arranged in nests and lined by resting cells presumably of alveolar origin. This feature may 
support the idea that the nests of stellate motilemyoepithelial cells, which have lost expression 
of the main myoepithelial suprabasal markers, but retained affinity for VIM, are the 
precursors of cartilage, indicating that these cells have completed their transformation into 
mesenchymal elements. In benign and malignant myoepithelial tumours, VIM labeling in all 
cases, loss of all other suprabasal myoepithelial markers, and the scant positivity to CK14 in 
spindle cells were indicative of a prevailing expression of the myoepithelium motile state 
and a possible passage from simple myoepithelial cells to mesenchymal fibroblasts. In our 
study, evidence of the myoepithelial cells shifting to a mesenchymal phenotype, shown by the 
loss of CK14, CK5/6, and p63 expression, was reinforced by the discontinuous labeling of 
spindle cells for Alpha-SMA, a marker of both myoepithelial cells and myofibroblasts, which 
was completely lost in stellate motile cells that have supposedly become fibroblasts. Further 
confirmation studies by Tsuda et al. [18] reported the occurrence of myofibroblasts with 
remnants of CK14 expression (described as “converted myoepithelial cells”). In the cases 
examined in the present study, CK14 progressively faded, therefore indicating a loss of the 
(myo-)epithelial phenotype. These results support the EMT hypothesis involving a 
myoepithelial-like state [19], which undergoes a myoepithelial mesenchymal transition 
(MMT). This hypothesis was confirmed in the dog by Gartner et al. [20] who stated that in 
 117 
 
 
mammary tumours one of the steps in the evolution ofmesenchymal cells involves the 
expression of typical myoepithelial traits. An interesting result of the present study was the 
positivity to ER found in 12/29 suprabasalmyoepithelial cells and 9/29 stellate cells of 
carcinoma in benign-mixed tumours and complex carcinomas. Two isoforms of ER receptors 
have been described, namely, ER-α and ER-β, the latter being the only form expressed in the 
nuclei of isolated basalmyoepithelial cells [8]. The antibody used in the present investigation 
was inclusive of both isoforms: both luminal and basal/stellate cells were labeled, presumably 
luminal cells by ER- β and basal/stellate cells by ER-α. 
Conclusions 
In conclusion, the suprabasal myoepithelial cells were well characterized by p63 and CK14 
and to a lesser extent by the other marker used. The motile myoepithelial cells are instead 
characterized by Alpha-SMA and VIM and loss of CK14, CK5/6, and p63 (Figure 2). The 
present study also demonstrated ER in both luminal epithelial and suprabasal/stellate 
myoepithelial cells (the latter in about half of the cases) and that ER expression is not 
influenced by the resting/motile phase. Therefore, in serial or multistained sections, 
immunohistochemistry to ER in combination with p63 and CK14 may serve to avoid 
erroneous identification of luminal or myoepithelial cells in canine mammary tumours. 
The trend of preserved Alpha-SMA and VIM expression in spindle cells, and only VIM 
positivity in stellate motile cells as well as the decreased p63 expression in both motile types, 
supports the hypothesis of the EMT involving a myoepithelial-like state [19] in MMT. The 
spindle motile cell could be considered an earlier transformation than the stellate cell towards 
a mesenchymal phenotype. 
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Figures 
 
Fig. 1: Suprabasal myoepithelial cells: resting (thick arrows) and proliferative (thin arrows) 
cells. Immunohistochemical expression of a panel of antibodies applied by IHC, 63x 
(A) Hematoxylin-eosin; (B) anti-CK19 antibodies labeling the cytoplasm; (C) anti-ER 
antibodies labeling the nuclei; (D) anti-CK 5/6 antibodies labeling the cytoplasm; (E) anti-
CK14 antibodies labeling the cytoplasm; (F) anti-VIM antibodies labeling the cytoplasm; (G) 
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anti-Alpha-SMA antibodies labeling the cytoplasmic membrane; (H) anti-p63 antibodies 
labeling the nuclei. 
 
Fig. 2: Motile myoepithelial cells: spindle (asterisks) and stellate (stars) cells. 
Immunohistochemical expression of a panel of antibodies applied by IHC. 63x  
(A) Hematoxylin-eosin; (B) anti-CK19 antibodies labeling the cytoplasm; (C) anti-ER 
antibodies labeling the nuclei; (D) anti-CK 5/6 antibodies labeling the cytoplasm; (E) anti-
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CK14 antibodies labeling the cytoplasm; (F) anti-VIM antibodies labeling the cytoplasm; (G) 
anti-Alpha-SMA antibodies labeling the cytoplasmic membrane; (H) anti-p63 antibodies 
labeling the nuclei. 
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5. CD117 EXPRESSION INFLUENCES PROLIFERATION BUT NOT 
SURVIVAL IN CANINE MAMMARY TUMOURS 
 
 
 
 
 
 
 
Introduction  
C-Kit is a gene that encodes a membrane-associated tyrosine kinase growth factor receptor 
(CD117) (Yarden et al., 1987), composed of an extracellular ligand-binding region (5 
immunoglobulin-like domains), a single transmembrane spanning region (hydrophobic 
domain), and a cytoplasmic region which includes both the kinase (ATP-binding and 
phosphotransferase) and the juxtamembrane domains (Linnekin, 1999; Boissan et al., 2000). 
CD117 is expressed in various cell types during embryonic development and it promotes the 
migration, differentiation, proliferation, growth, adhesion, chemotaxis and survival of cells 
(Chian et al., 2001; Ronnstrand, 2004). CD117 has been shown to be expressed by neoplastic 
cells as well; in the dog most notably, in gastrointestinal stromal tumors (GIST) (Bettini et al., 
2003; Frost et al., 2003; Smith et al, 2009), in mast cell tumours (Gil da Costa et al., 2007; 
Thompson et al., 2011), neoplastic testes (Bush et al., 2011; Thorvaldsen et al., 2012), and 
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melanocytic tumours (Murakami et al., 2011; Gomes et al., 2012). Few studies have focused 
on the expression of CD117 in canine mammary tissue, and the difference in its expression 
between normal tissue and neoplastic benign or malignant change (Kubo et al., 1998; Morini 
et al., 2004; Sailasuta et al., 2008). Kubo et al. (1998) investigated the expression of the 
canine c-Kit oncogene in mammary tumours with the aid of  RT-PCR; the results showed a 
significant higher level of transcription in adenocarcinoma than in malignant mixed tumours.  
Morini et al. (2004) and Sailasuta et al. (2008) evaluated CD117 expression using 
immunohistochemistry. Morini et al. (2004) found a weak to moderate cytoplasmic staining 
in ductal and acinar epithelial cells of the normal canine mammary gland, and a weak to 
moderate cytoplasmic staining in benign and malignant mammary tumours.  Sailasuta et al. 
(2008) found either membranous, cytoplasmic staining or both, but they did not see a 
statistically significant difference between the CD117 expression and histological type, 
histological malignancy, nuclear differentiation or grade of mammary gland tumour.  
Since c-Kit is a proto-oncogene that encodes a transmembrane tyrosine kinase growth factor 
receptor and stimulates cell proliferation, it plays a crucial role in determining existence of a 
correlation between c-Kit expression and  Ki67 index. A correlation between aberrant CD117 
expression and increased cell proliferation in canine mast cell tumours has been reported (Gil 
da Costa et al., 2007; Webster et al., 2007; Thompson et al., 2011). Therefore, the aims of the 
present study were (1) to characterize the immunohistochemical staining of CD117 in normal 
and neoplastic mammary tissue of the dog, and (2) to correlate CD117 immunohistochemical 
results with mammary histotype, histological stage (invasiveness), Ki67 index and patient 
survival time. 
Materials And Methods 
Study material 
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In this study 49 samples of normal and neoplastic canine mammary tissue were examined. 
The specimens  were retrieved from the archive of the  Veterinary Pathology Division of the 
Department of Veterinary Medical Sciences of the University of Bologna. The samples 
included 8 normal, hyperplastic and dysplastic mammary tissue specimens, 11 cases of benign 
mammary tumours and 30 cases of malignant mammary neoplasms. Tissue specimens were 
fixed in 10% buffered formalin and embedded in paraffin. Sections of 4 µm were stained with 
Haematoxylin–Eosin (H-E) and observed microscopically. The samples were then 
histologically diagnosed according to the criteria set by Misdorp et al., (1999). In malignant 
tumours, the histologic stage of invasion was determined according to Gilbertson et al. (1983) 
as follows: stage 0 = tumours without stromal invasion; stage I = tumours with stromal 
invasion, stage II = tumours with neoplastic emboli in vessels or lymph node metastases (or 
both). As a follow-up the owners/referring veterinarians of all cases of malignant tumours 
were contacted in order to obtain information regarding survival time and the cause of death.   
Immunohistochemistry 
Two consecutive sections were dewaxed in toluene and rehydrated. Endogenous peroxidase 
was blocked by immersion in 3% hydrogen peroxide for 30 minutes. Sections were then 
rinsed in Tris buffer, immersed in citrate buffer (2.1g citric acid monohydrate/litre of distilled 
water), pH 6.0, incubated for 2 cycles of 5 minutes (anti-CD117 antibody) and for 4 cycles of 
5 minutes each (anti-Ki67 antibody) in a microwave oven at 750W, and allowed to cool down 
at room temperature for approximately 20 minutes.  
The antibodies (CD117, polyclonal, Dako Cytomation, 1:100 dilution with phosphate-
buffered saline solution and 1% BSA) and anti-Ki67 antibody (clone MIB-1, Dako 
Cytomation, 1:30 dilution with phosphate-buffered solution) were applied, and the sections 
were incubated overnight at 4ºC. Sites of primary antibody binding were identified using a 
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commercial Streptavidin-biotin-peroxidase kit (LSAB KIT, Dako) and diaminobenzidine as 
the chromogen (0.04% for 10 minutes). The sections were then counterstained with 
Papanicolaou Haematoxylin, rinsed in tap water, dehydrated and cover-slipped.  
Sections of  a well differentiated canine mast cell tumour were used as positive controls for 
CD117 and the basal layer of the epidermis served as an internal positive control for Ki67. 
Negative controls were prepared by incubating the slides with an isotype-matched nonspecific 
antibody. 
CD117 evaluation 
The slides were blindly evaluated by 2 board-certified anatomical pathologists (C.B. and 
B.B.) for CD117 immunoreactivity. The results were considered positive when a brown 
labelling of the cells was present, and negative when no immunoreactivity was noted on the 
section (CD117 expression). 
The pattern of positivity of the cells for CD117 was classified as membranous (M) (brown 
labelling of the cytoplasmic membrane), cytoplasmic (C) (diffuse brown labelling of the 
cytoplasm) or membranous-cytoplasmic (MC) (simultaneous cytoplasmic and membranous 
expressions). CD117 extension was the percentage of positively labelled cells (extension) 
evaluated as follows: 0= negative (0%), 1= focal (1-19%), 2= intermediate (20-49%), 3= 
diffuse (> 50%)  as described by Gomes et al. (2012) modified.  
Ki67 index 
Ki67 immunoistochemical labelling was blindly evaluated by a single pathologist (G.B.) 
using a 40x objective to select 5 fields with the highest Ki67 positivity; areas with necrosis or 
inflammation were avoided. Ki67 index was calculated as the percentage of labelled nuclei 
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compared with the total nuclear area of the field according to a previously described method 
(Sarli et al., 2002). 
Statistics 
The correlation between CD117 expression, CD117 pattern or CD117 extension vs  type of 
mammary lesion, histological classification, histological stage and Ki67 index was tested with 
the Pearson’s chi-square (χ2) test. Ki67 index was tested with the Shapiro Wilk’s W analysis 
for normality and appeared non-normally distributed. Due to this abnormal distribution, Ki67 
index in CD117 expression groups (positive vs negative) and CD117 patterns were tested 
with the non-parametric Kruskal Wallis ANOVA Median test. Survival analysis was used to 
compare Kaplan Meyer estimated curves in 2 groups (CD117 expression in the 3 groups 
(CD117 pattern) or in the 4 groups (CD117 exension) selecting only those cases in which 
death was due with no doubt to the tumour. In all tests a value of P<0.05 was considered to be 
statistically significant. 
Results  
The 49 cases were as follows: 3 cases of normal mammary tissue, 5 cases of hyperplasia, 11 
benign tumours (4 tubulo-papillary adenomas, 1 simple adenoma, 1 complex adenoma, 3 
fibroadenomas, and 2 benign mixed tumours); 30 malignant tumours (10 solid carcinomas, 4 
carcinoma in benign tumours, 8 simple tubulo-papillary carcinomas, 5 complex carcinomas, 2 
anaplastic carcinomas, and 1 squamous carcinoma). Of these 30 malignant tumours, 2 were 
found to be histological stage 0, 12 stage I, and 16  stage II. The mast cell tumour used as 
positive control showed a strong membranous positivity in all neoplastic cells for CD117 
expression. Ki67 expression was evident in the nuclei of the basal layer of epidermis. 
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Information about the patients’ survival time of 22 out of the 30 malignant tumours studied 
was retrieved, and in 13 cases death was correlated with the presence of metastasis (Table 1). 
Table 1: Individual data  
N° HISTOTYPE STAGE 
CD117 
EXPRESSION 
CD117 
PATTERN 
CD117 
EXTENSION 
Ki67 
index 
SURVIVAL 
RATE 
(MONTHS) 
1 Normal   P M 3 7,9   
2 Normal   P M/C 3 5,78   
3 Normal    P C 1 4,27   
4  ADH   P C 1 3,34   
5 ADH   P C 1 3,56   
6 ADH   N   0 2,84   
7 Hyperplasia   N   0 6,5   
8 Hyperplasia   P M 3 6,16   
9 Tubpap adenoma   P C 1 4,15   
10 Tubpap adenoma   P C 2 3,07   
11 Tubpap adenoma   P C 3 2,79   
12 Tubpap adenoma   N   0 3,43   
13 Complex adenoma   N   0 2,7   
14 Simple adenoma   N   0 14,34   
15 Fibroadenoma   P C 1 5,36   
16 Fibroadenoma   P M 3 25,07   
17 Fibroadenoma   N   0 1,66   
18 BMT   N   0 3,07   
19 BMT   N   0 8,45   
20 Solid carcinoma 2 P C 1 9,83 36 
21 Solid carcinoma 1 P C 2 3,85 24 
22 Solid carcinoma 2 P C 2 5,77 NA 
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23 Solid carcinoma 0 P M/C 3 8,53 NA 
24 Solid carcinoma 1 P M/C 3 6,49 NA 
25 Solid carcinoma 2 P M/C 3 23,18 3 
26 Solid carcinoma 2 P M/C 3 8,18 24 
27 Solid carcinoma 1 P M/C 3 9,39 24 
28 Solid carcinoma 1 N   0 4,26 NA 
29 Solid carcinoma 2 N   0 1,86 1 
30 CBT 2 P M/C 3 8,14 24 
31 CBT 2 P M/C 3 13,85 48 
32 CBT 1 P C  3 5,95 1 
33 CBT 1 N   0 2,65 48 
34 Tubpap carc 2 P C 1 8,21 12 
35 Tubpap carc 1 P C 2 2,78 6 
36 Tubpap carc 1 P M/C 2 5,58 NA 
37 Tubpap carc 2 P C 3 6,67 1 
38 Tubpap carc 2 P M/C 3 9,22 NA 
39 Tubpap carc 2 N   0 1,96 2 
40 Tubpap carc 1 N   0 2,45 12 
41 Tubpap carc 1 N   0 6,26 NA 
42 Complex carc 2 P C 2 3,67 24 
43 Complex carc 0 N   0 2,56 5 
44 Complex carc 2 N   0 2,95 6 
45 Complex carc 1 N   0 2,13 A 
46 Complex carc 1 N   0 1,97 N/A 
47 Anaplastic carc 2 P C 3 8,25 2 
48 Anaplastic carc 2 P C 2 5,51 2 
49 Squamous carc 2 P C 3 8,16 A 
ADH: atypical ductal hyperplasia. Tubpap adenoma: tubulo-papillary adenoma. BMT: benign in mixed tumour. CBT: 
carcinoma in benign mixed tumours. Tubpap carc: tubulo-papillary carcinoma. Comlex carc: complex carcinoma. Anaplastic 
carc: anaplastic carcinoma. Squamous carc: squamous carcinoma. P: positive. N: negative. M: membranous. C: cytoplasmic. 
M/C: membranous and cytoplasmic. NA: available. A: alive 
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Normal mammary tissue and hyperplasia 
CD117 expression was observed in the alveolar and ductal mammary epithelium in 6 of the 8 
examined normal and hyperplastic mammary tissues. No expression was detected in the 
myoepithelial and in the stromal cells in any of the cases. The remaining 2 cases (mammary 
hyperplasia) were negative. The CD117 pattern was M in two cases (1 normal mammary 
tissue and 1 hyperplasia), C in 3 cases (1 normal mammary tissue and 2 hyperplasias), M/C in 
1 normal mammary tissue (Fig. 1a). CD117 extension was focal in 3 cases (1 normal 
mammary tissue and 2 hyperplasias) and diffuse in the remaining (1 normal mammary tissue, 
2 hyperplasias) (Table 1, Fig. 2a, 2d, 2g). 
Benign mammary tumours 
In benign mammary tumours CD117 was expressed exclusively in the epithelial cells in 5 out 
of 11 cases. Regarding CD117 pattern, 3  of the 4 tubulo-papillary adenomas were positive 
with C labelling and 1 was negative. Two positive cases out of 3 of the fibroadenoma type  
showed a C and a M pattern respectively (Fig. 1b). The remaining fibroadenoma as well the 
simple adenoma, the complex adenoma, and the 2 benign mixed tumours did not express 
CD117 . In the positive cases the labelling extension was focal in 2 cases (1 tubulo-papillary 
adenoma and 1 fibroadenoma), intermediate in a tubulo-papillary adenoma and diffuse in 2 
cases (1 tubulo-papillary adenoma and 1 fibroadenoma). All the data are reported in Table 1 
and Fig. 2a, 2d, 2g. 
Malignant mammary tumours 
CD117 immunoexpression was present in 20 of the 30 malignant tumours, namely 8 solid 
carcinomas, 3 carcinoma in benign mixed tumours, 5 tubulo-papillary carcinomas, 1 complex 
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carcinoma, 2 anaplastic carcinomas and 1 squamous cell carcinoma. For the labelling 
location, the positive cells were all epithelial cells except for one case that presented both 
epithelial and myoepithelial staining (carcinoma in benign tumour). The 8 solid carcinomas 
displayed different CD117 pattern: C reactivity in 3 cases and M/C in 5 cases (Fig. 1d, 1e, 1f). 
The 3 carcinomas in benign mixed tumours showed C positivity in one case, and M/C in the 
other 2 cases (Fig. 1c). The cartilaginous component of the latter 3 cases was negative for 
CD117 (Fig. 1c). The 5 tubulo-papillary carcinomas displayed C in 3 cases and M/C pattern 
in 2 cases. The 2 anaplastic carcinoma, complex carcinoma and squamous cell carcinoma 
showed C expression. The labelling extension was focal in 3 cases (1 solid carcinoma, 1 
tubulo-papillary, 1 complex carcinoma), intermediate in 5 cases (2 solid carcinomas, 2 tubulo-
papillary carcinomas, 1 anaplastic carcinoma) and diffuse in 12 cases (5 solid carcinomas, 3 
carcinomas in benign  mixed tumours, 2 tubulo-papillary carcinomas, 1 anaplastic carcinoma, 
1 squamous cell carcinoma) (Table 1, Fig. 2).  
Correlation between the three CD117 variables and type of mammary lesion, 
malignant histotypes and histological stage  
None of the 3 CD117 variables (CD117 expression, CD117 pattern and CD117 extension) 
appeared to be associated with the different mammary lesion types (normal/hyperplasia, 
benign tumours, malignant tumours), histotypes and invasiveness. Only in malignant tumours 
was an association between CD117 pattern and histological type  evident (R=0.37, P=0.043, 
Pearson test) (Table 2). 
Correlation between CD117 expression, pattern, extension and Ki67 
All the 3 CD117 variables were significantly associated with Ki67 index (Table 2) (Fig. 3a, 
3c, 3e). Comparing the Ki67 value of the CD117 positive cases (CD117 expression) vs those 
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negative, only in malignant tumours was a significantly higher Ki67 value apparent (P<0.001, 
Kruskall-Wallis test) (Fig. 3a). The tumours with both cytoplasmic and membranous staining 
patterns showed a significantly higher range and higher median value of the Ki67 index 
compared to cases with only cytoplasmic expression (P<0.001, Kruskall-Wallis test), and 
were both significantly higher than negative cases (P<0.01, Kruskall-Wallis test) (Fig. 3c).  
Ki67 showed values increased progressively from negative cases to those presenting diffuse 
extension staining of CD117 (P<0.001, R=0.61, Spearman test) (Fig. 3e) (Table 2).  
Correlation between CD117 expression, pattern, extension and patient survival 
time 
Survival time was available for 22 female dogs bearing malignant tumours. In only 13 cases 
death was due to the tumour and only in these cases survival analysis was performed. Survival 
analysis did not reveal any differences in the comparison of the 2 groups of CD117 
expression (positive vs negative) (P=0.91 Survival analysis) (Fig. 3b) or the 3 groups of 
CD117 pattern (membranous, cytoplasmic, cytoplasmic+membranous) (P=0.46 Survival 
analysis) (Fig. 3d) and the four groups of CD117 extension (absent, focal, intermediate, 
diffuse) (P=0.85 Survival analysis) (Fig. 3f) (Table 2).  
Table 2: R and P values of the Pearson chi square test 
 Nmg/Hyp vs BT 
vs MT 
Histotypes of 
MT 
Invasiveness Ki67 index 
 R P R P R P R P 
CD117 expression -0.004 0.97 0.21 0.25 -0.30 0.10 -0.35 0.014 
CD117 pattern 0.10 0.47 0.37 0.043 -0.16 0.37 -0.55 <0.001 
CD117 extension 0.14 0.33 -0.15 0.40 0.25 0.17 0.51 <0.001 
Nmg = normal mammary gland; Hyp = hyperplasia; BT = benign tumour; MT = malignant tumour. 
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Discussion 
Normal human breast tissues strongly express the c-Kit proto-oncogene product on the cell 
membrane and/or cytoplasm of alveolar and ductal cells (Chui et al., 1996; Tomasino et al., 
2009). Regarding benign and malignant human breast diseases discordant results are reported 
in literature; in fact, in several studies the c-Kit proto-oncogene product was detected 
heterogeneously with a reduced immunoreactive score in benign lesions and even less 
represented in breast cancer (Chui et al., 1996; Tomasino et al., 2009; Kondi-Pafiti et al., 
2010). Other Authors found an increased expression of CD117 in poorly differentiated breast 
cancer (Diallo et al., 2006; Kanapathy Pillai et al., 2012). 
By now, only few studies have investigated the expression of CD117 in canine mammary 
tumours (Kubo et al., 1998; Morini et al., 2004; Sailasuta et al., 2008), but with no clear 
results about the importance of this receptor. 
The present study evaluated CD117 expression, pattern and extension in canine mammary 
tissue (normal and neoplastic), correlating the results not only to different mammary lesions, 
histotypes, histological stage and survival, but also with a marker of proliferation Ki67. 
Considering CD117 expression, the present results, also in agreement with Sailasuta et al., 
(2008), showed no statistically significant differences between the expression of CD117 
(positivity/negativity) and different histotypes. Our results demonstrated a distinctive decrease 
in CD117 expression in benign tumours comparing with normal tissue (similarly to what seen 
in human studies), but with no such a distinctive decrease in CD117 expression in malignant 
tumours as  reported in some human breast cancer studies (Chui et al., 1996; Tomasino et al., 
2009; Kondi-Pafiti et al., 2010). This may be linked to canine tumour heterogenicity or 
perhaps because malignant mammary tumours are usually very well differentiated and present 
a less malignant behaviour than their of the human counterparts.  
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Regarding the CD117 pattern, in normal mammary glands all three patterns were found. This 
result may be indicative of functional activity of CD117 irrespective of the type of positivity. 
In benign tumours, the present results highlighted the absence of simultaneous M/C 
expression, as the cases were completely C or M. With the progression of the lesions 
(malignant tumours), C and M/C, but not M only, were present. The decreasing trend of M 
only expression to the simultaneous M/C expression or even only C can be interpreted as an 
accumulation of receptor proteins that did not undergo final maturation, or an excessive 
internalization of activated c-Kit and/or an abnormal synthesis of the receptor, preventing it 
from reaching the transmembrane region as suggested by different authors (Torres-Cabala et 
al., 2009; Gomes et al., 2012). A significant correlation between CD117 pattern and 
histotypes of malignant tumours was found (R=0.37, P=0.043, Pearson test) indicating that 
the localization of this type of receptor may be associated with the morphological type of the 
malignant mammary carcinoma with an increasing percentage of “only cytoplasmic” pattern 
from the well differentiated to the less differentiated histotypes. 
Analyzing the CD117 extension (percent of positive cells) it can be observed that all the 
extension types (i.e. decrease of positivity) are present in the different type of mammary 
lesion except for the “intermediate” in the group of normal mammary tissue and hyperplasia, 
which could be due to the low number of cases; in addition, the extension of the positivity 
was not related to the type of mammary lesion and malignant histotypes.  
None of the three parameters (CD117 expression, pattern and extension) were shown to be 
correlated with invasiveness, although, this association has been observed in pancreatic 
cancer cells (Yasuda et al., 2006). 
Similar negative findings occurred correlating the three parameters (CD117 expression, 
pattern and extension) with survival time, i.e. there was no correlation of CD117  and patient 
survival. 
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The usefulness of CD117 results changes when these are correlated with the Ki67 index. 
Proliferative activity is strictly associated not only to positive/negative CD117 expression, but 
also to the type of expression (CD117 pattern) and to the percentage of labelling (CD117 
extension), suggesting in canine mammary tumours the existence of a link between the 
presence of the receptor and the proliferative activity. This also suggests that the M, M/C as 
well as only C expression are able to induce proliferation, with decreasing grades of signal 
from M to M/C to C only, demonstrated by our results in mammary malignant neoplasms. Gil 
da Costa et al. (2007) as well, in their paper about canine mast cell tumours results have 
highlighted a strong correlation between C (altered) CD117 immunoexpression and increased 
cell proliferation. These results suggest that even a C expression pattern is  able to partially 
increase cellular proliferation as assessed by the Ki67 labelling index. As noted above, the 
different patterns of expression, which have been identified in the juxtamembrane domain of 
c-Kit in certain canine mast cell tumours which are attributed to point mutations, deletions, 
and duplications (Preziosi et al., 2004), seem to apply to mammary neoplasms as well. It is 
well-known (Regan et al., 2012) that the c-Kit  signaling pathway is required for the normal 
function of mammary epithelial progenitors.  
Conclusions 
The M, M/C and C expression, existing in the normal mammary gland as well as in neoplastic 
growth, suggest that in transformed mammary cells the c-Kit signalling network may be 
activated downstream of the receptor. The demonstration that CD117 expression, pattern and 
extension in canine mammary tumours is correlated with proliferative activity may provide 
evidence for the utility of tyrosine kinase inhibitors in the therapy of neoplastic mammary 
disease. 
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Figures 
 
Fig. 1: Immunohistochemistry (IHC) of CD117 expression, pattern and extension. 
A) Dog, normal mammary gland. Normal mammary ducts and lobules show a cytoplasmic 
and membranous pattern and diffuse  IHC CD117extension. Bar, 50µm. b) Dog, mammary 
gland, fibroadenoma. Epithelial cells show a membranous pattern and diffuse extension to 
IHC CD117. Bar, 100µm. c) Dog, mammary gland, carcinoma in benign mixed tumour. 
Evidence of  membranous and cytoplasmic pattern and diffuse extension to IHC CD117 in the 
epithelial component of the tumour. The cartilaginous component is negative. Bar, 500 µm. d) 
Dog, mammary gland, solid carcinoma. The cells to the left with squamous metaplasia show 
cytoplasmic positivity to IHC CD117, while the spindle-shaped epithelial cells on the right 
express membranous positivity. Bar, 200 µm. e) Dog, mammary gland, solid carcinoma. The 
epithelial cells present a cytoplasmic and membranous pattern and intermediate extension to 
IHC CD117. Bar, 100 µm. f) Dog, mammary gland, solid carcinoma. The epithelial cells 
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present a membranous and cytoplasmic pattern and diffuse extension to IHC CD117. Bar, 100 
µm. 
 
Fig. 2: CD117 expression, pattern and extension. 
CD117 expression (i.e. positive or negative immunohistochemical staining) in the 3 
categories of tissues (a) in the histotypes of malignant tumours (b) and in the 3 histological 
stages (c). CD117 pattern (i.e. the localization of the immunohistochemical stain as 
membranous and/or cytoplasmic) in the 3 categories of tissues (d), in the histotypes of 
malignant tumours (e) and in the 3 histological stages (f). CD117 extension (i.e. the amounts 
of tissue stained) in the 3 categories  of tissues (g), in the histotypes of malignant tumours (h) 
and in the 3 histological stages (i).   
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Fig. 3: Correlation between Ki67 index and CD117 expression, pattern, extension and 
survival rate.  
Ki67 index of the malignant tumours in the two groups (positive; negative) of CD117 
expression (a), in the 3 groups (negative; membranous/cytoplasmic; C=cytoplasmic) of 
CD117 pattern (b) and in the 4 groups (negative, focal, intermediate, diffuse) of CD117 
expression (c). Kaplan-Meyer estimated curves in the two groups (positive; negative) of 
CD117 expression (d), in the 3 groups (negative; membranous/cytoplasmic; cytoplasmic) of 
CD117 pattern (e) and in the 4 groups (negative, focal, intermediate, diffuse) of CD117 
expression (f).  
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6. CONCLUSIONS 
In Human Medicine, the discovery of molecular subtypes of breast cancer has produced  
further proofs of the fact that biological diversity consequently denies a unique therapeutic 
approach (Peppercorn et al., 2008). The therapeutic approach to breast cancer varies 
according to the different molecular phenotypes and in the recent past it was highlighted the 
necessity to identify the molecular phenotypes also for the lymph node metastasis and 
eventual systemic metastases (Aitken et al., 2010). 
The information acquired from the research conducted in the past three years regarding the 
identification of molecular phenotypes in feline and canine mammary tumours revealed the 
importance of the phenotyping to fill current gaps regarding prognosis and a targeted 
therapeutic approach, since the primary tumour phenotype does not always overlap with that 
of its metastasis. The primary tumour phenotype assumes a predictive therapeutic role only in 
concordant cases, meaning that there should be a concomitant evaluation of both the primary 
tumour and its lymph node metastasis. Treatment planning based only on the primary tumour 
phenotype can lead to therapeutic failures if the lymph node metastatic phenotype differs 
from that of the primary tumour. To the best of our  knowledge, this was the first report that 
identified molecular phenotypes in feline mammary tumours.  
Regarding the correlation between primary mammary site phenotypes and the phenotypes  of 
systemic metastases, the existence of both biological phenomena of concordance and 
discordance in metastatic sites has been confirmed. The prevalence of concordance between 
primary and metastatic sites supports the predictive therapeutic value of the primary tumour 
phenotype, minimizing any margin of error which can occur in rare discordant cases. 
The research focused on various aspects of myoepithelial cells allowed to better characterized 
the four different myoepithelial cell morphological types in the normal and neoplastic 
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mammary gland using a panel of antibodies and confirmed the changes of myoepithelial cells 
towards mesenchyme from an myoepithelial to a mesenchymal phenotype. 
The investigation that was conducted for the study of CD117 demonstrated that its expression, 
pattern and extension in canine mammary tumours is correlated with proliferative activity 
may provide evidence for the utility of tyrosine kinase inhibitors in the therapy of neoplastic 
mammary disease. 
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